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Abstract 
 
 
The purpose of this study is to investigate specific contributing factors affecting quality 
assurance in the diagnosis of conventional cervical smears.  More than half of South-
African women fail to have one cervical smear in their lifetime and +/- 50% of those who 
do have cervical smears taken, are lost to follow-up. 
 
Since cervical cancer is the most common malignancy amongst women in developing 
countries, the medical profession will have to endeavor to screen a higher rate of women 
and ensure a 100% quality assurance with every patient treated in order to reduce the 
unacceptable high incidence of cervical carcinoma.  At this stage it seems like an 
impossible task to screen all women in South Africa, due to far-off rural areas, shortage 
of medical professionals and the lack of knowledge of some women of the necessity of 
cervical smears. 
 
Many newly qualified South-African doctors leave the country to go and work elsewhere.  
South Africa then in turn has to recruit doctors from other countries to staff the State 
hospitals and clinics.  Some areas have one doctor to thousands of patients, insufficient 
nursing personnel and inadequate equipment.  Doctors in some areas cannot cope with 
the volume of work and the long hours.  One has to accept that the quality of the 
management of some patients is affected negatively. 
 
There are a number of medico-legal issues (world wide) in relation to aspects of cervical 
cancer prevention practices which are controversial and are of particular concern to all of 
those involved in cervical cancer prevention.  Various countries have therefore formed 
different national organizations to address the medico-legal issues in screening for the 
prevention of cancer.  These organizations monitors procedures, internal quality control 
as well as external quality control. 
 
In South Africa, medico-legal cases are not so prevalent, but may become so shortly.  The 
South-African medical professionals therefore have to ensure that their quality of work 
conforms to accepted good practice in all circumstances.  State hospitals serve thousands 
of patients per month and it is an every day occurrence to see long queues of patients 
sitting waiting for doctors and who often have to come back the following day.  The 
situation appears to be much improved in private practice and since patients have medical 
cover and accessible medical facilities. 
 
Since cervical cancer is the most common malignancy amongst women in developing 
countries, the medical profession will have to endeavor to screen a higher rate of women 
and ensure a 100% quality assurance with every patient treated in order to reduce the 
unacceptable high incidence of cervical carcinoma.  At this stage it seems like an 
impossible task to screen 100% of women in South Africa, due to far-off rural areas, the 
shortage of medical professionals and ignorance of patients.   
 
Quality assurance is therefore of paramount importance to every medical professional for 
every patient treated. 
 
Laboratories all worldwide have been, or are in the process of being accredited by their 
specific accreditation authorities.  The main reason for this is improvement of quality 
control and therefore quality assurance. 
 
The South African National Accreditation Society (SANAS) now accredits various 
laboratories in South Africa with the view of accreditting all laboratories within a certain 
time limit.  The Ampath laboratory Port Elizabeth was successfully accredited during 
2001.  Accredited laboratories have to uphold a very high degree of quality to remain 
accredited.  A team of professionals inspects the laboratory every 2 years and other 
quality assurance staff inspects the laboratories every few months.  All aspects of the 
laboratory are checked, e.g. the qualification of staff, their registration with the Health 
Professions Council of South Africa (HPCSA), their curriculum vitaes, equipment, safety 
of the laboratory etc. etc. 
 
Since the laboratory chosen for this study, is accredited, the author evaluated every 
cervical smear that was received in the laboratory since the year 2000, with the following 
objectives in mind: 
 
• Whether the presence or absence of an endocervical component has an effect on 
the adequacy of cervical smears 
• To determine the effect of using smaller coverslips on quality assurance in the 
cytology laboratory 
• Evaluate the effect that manual re-screening of smears has on quality assurance in 
the cytology laboratory. 
 
As there is a shortage of cytotechnologists and pathologists worldwide, several countries 
make use of automated screening devices as primary screening or secondary screening 
for quality assurance.  These devices were tested in some laboratories in South Africa but 
were found to be very expensive and sensitivity and specificity were not up to standard.  
Sensitivity is a measure of the ability of a test to detect the abnormal - Sensitivity is the 
ratio of true positives to true positives + false negatives.  Specificity is a measure of the 
ability of a test to correctly identify the negative - Specificity is the ratio of true negative 
to true negatives + false positives.  The automated screening machines failed to identify 
abnormal cells amongst inflammatory cells, as well as in very blood stained smears.  
Several other problems also occurred and an increasing number of smears had to be 
manually rescreened, thus making this exercise costly and not helpful as a quality 
assurance instrument. 
 
The slides used for this thesis, have been retrieved from the archives of the Ampath 
laboratory in Port Elizabeth. 
 
Fourteen specific contributing factors affecting quality assurance in the diagnosis of 
cervical smears are also discussed and conclusions and recommendations given. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
What is cytology? 
In pathology, cytology refers to the study under a microscope of individual cells to 
establish a cause of disease, most commonly for premalignant or malignant conditions. 
Cells are stained with a number of tinctorial or other stains that enable the nuclear and 
cytoplasmic features of cells to be examined. 
The cells that are examined in cytological samples usually originate from epithelial, or 
epithelial like tissues, and are most simply obtained as the epithelium exfoliates. These 
cells may be naturally exfoliated as in sputa or urine, or the cells may be mechanically 
obtained by brushing or scraping.  
Sometimes cells may be obtained by the use of fine needle aspiration (FNA) that enables 
more deep-seated tissues that would not necessarily exfoliate, to be sampled. 
Cytological specimens are usually divided into gynaecological and non-gynaecological 
samples. The former are from women within cervical screening programs, the latter 
generally being diagnostic samples from patients with suspected disease.  
Cervical smears form part of gynaecological (Fig. 1) cytology. Normal cell types that 
may be seen within a cervical smear include epithelial cells from the ecto- and 
endocervix, the vagina and endometrium.  
 
Inflammatory cells, red blood cells, fungi and viral cytopathic effect may also be seen (Geisinger, 2003).  
 
 
 
 Figure 1:  Female genital tract (Taken from http://www.nlm.nih.gov/medline) 
 
What is the problem? 
 
Only 41% of women in South Africa present for cervical sampling “some or other time in 
their lives”!! Of these, less than 50% follow their recommendations as per health 
professional, doctor or pathologist instructions.  Therefore, the diagnosis of ASC-US 
(Atypical squamous cells of uncertain significance) or even LSIL (Low grade squamous 
intra-epithelial lesion) may not have any impact on the patient and she may abscond for 
the rest of her life. 
 
These patients may be lost to follow-up and the ideal situation would be for them to wait 
for their results and be treated or treatment recommended at the initial consultation   
(Cross, 1997).  According to South African government legislation, a woman is entitled 
to go for cervical smear screening 3 times during her lifetime.    Private patients and even 
those with medical aids seem to go for cervical smears as required, i.e. pre-natal or post 
natal, with irregular bleeds etc.  (Sankaranarayanan, 2003).    
 
Any family practitioner or internist etc., when seeing female patients for non-
gynaecological problems, should not miss the opportunity to obtain a cervical smear 
whenever appropriate (Dudding, 1995). 
Since cervical cancer is the most common malignancy amongst women in developing 
countries, the medical profession will have to endeavour to screen a higher rate of women 
and ensure a 100% quality assurance with every patient treated in order to reduce the 
unacceptable high incidence rate of cervical carcinoma.  At this stage it seems like an 
impossible task to screen 100% of women in South Africa, due to far-off rural areas, the 
shortage of medical professionals and ignorance of patients.   
 
Many newly qualified South-African health professionals leave the country to go and 
work elsewhere.  South Africa then in turn has to recruit health professionals from other 
countries to staff the State hospitals and clinics.  Some areas have one doctor to 
thousands of patients and insufficient nursing personnel and inadequate equipment.  
Health professionals in some areas cannot cope with the volume of work and the long 
hours.  One has to accept that the quality of the management of some patients is affected 
negatively (own observation). 
 
What is the solution to the problem? 
 
Although various authorities have been discussing quality assurance globally since the 
mid-eighties, accreditation of medical laboratories only became compulsory in 1996.  
The necessity for compulsory accreditation was the result of medico-legal cases in 
different countries, concerning false-negative cytological results. In South Africa, 
medico-legal cases are not so prevalent, but may become so shortly.   
 
Quality assurance is therefore of key importance in the evaluation of cervical smears 
(Benedict and Murphy, 1985).   Quality assurance applies to all clinical and non-clinical 
staff involved and therefore it seems worth the money and trouble to train every member 
of staff that we have access to and make them aware of the statistics and the absolute 
importance of QUALITY ASSURANCE (Faulkner, 2003). 
 What is quality? 
The concept ‘quality’ can be described in many ways.  According to the international 
standard ISO 8402,  ‘quality’ is a totality of characteristics of an entity that bear on its 
ability to satisfy stated and implied needs.  The achievement of satisfactory quality 
involves all stages of the quality loop as a whole (Linko, et al., 2001).  
 
The operation of laboratory medicine in patient care, monitoring and diagnosis is strongly 
linked to measurements and observations applied to laboratory samples.  Producing 
reliable results within a reasonable turnaround time is the ultimate responsibility of 
medical laboratories.  The total quality of the laboratory service, from the pre-analytical 
phase through the analytical phase to reporting, is to support the clinicians’ decision 
making. 
 
The proper management of laboratory processes needs supervised personnel doing the 
right things in the right way.  Well-defined rules are necessary for this management, as 
the numerous processes range from sample taking to reporting (Linko, et al., 2001).   
 
International standards, guides and legislation support the establishment and 
implementation of quality systems.  The quality of laboratory results, as being the end 
products of the process, thus strongly reflects the internal efficiency and the outcome of 
quality assurance (Linko, et al., 2001). 
 
1.1   Contributing factors affecting quality assurance in the 
diagnosis of cervical smears: 
The following procedures should be tested and medical professionals informed about 
these measures.  These individuals should be monitored and statistical feedback provided 
in order to audit their extra training (Faulkner, 2003). 
 
1.1.1. Taking of smear:  
Collection of a cervical cytology specimen (Fig. 2) is usually performed with the patient 
in the lithotomy position (patient on her back with hips and knees flexed and the thighs 
separated).   
 
 
Figure 2:  Illustration of taking of cervical smear (Taken from http://www.nlm.nih.gov/medline) 
 
 
A sterile or single-use bivalve speculum of appropriate size is inserted into the vagina 
without lubrication, since lubrication materials may obscure or otherwise negatively 
affect the cells.  Warm water may be used to facilitate insertion of the speculum.  The 
position of the speculum should allow for complete visualization of the cervical os and 
ectocervix.  The entire vagina is also checked for any ulcers or suspicious areas (Fig. 3). 
 
There are various ways of taking cervical, vaginal and vault smears (Kieswetter, et al., 
2001).  Various devices are used according to the clinician’s choice or the finances 
available (Valenzuela, 2001).    
 
The crucial point is to be able to visualize the area, to take a satisfactory sample (including transformation zone if applicable) and then 
to transfer most of these cells on to the glass slide.  The main source of false negative diagnoses is the insufficient gaining of material 
from the endocervical canal (Geisinger, 2003). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Transformation zone (Taken from The Bethesda System) 
 
 
Various spatulas are available to obtain cells from the cervix and the application of cells 
onto a glass slide.  Some health professionals prefer wooden spatulas and others the cyto-
brush.  The main concern is to get an adequate smear from the correct area of the ecto- or 
endocervix, post-fornix or vaginal wall (Diag. 1). 
 
1.1.2. Fixation of smear:  
The fixation of a smear is very important.  Poor fixation makes cells unsuitable for 
cytological evaluation.  All health professionals are supplied with cans of aerosol spray-
fixative, which is alcohol and carbowax based (SOP-LP-PCYTO-013).   
 
1.1.3.   Marking of the slide: 
 
 
Squamocolumnar 
junction
Transformation zone
Cervix 
Vagina 
The smear should immediately be marked with a pencil or diamond pen on the frosted 
end of the slide to accurately identify the slide (SOP-WI-PCYTO-001). 
 
 
1.1.4. Submission of clinical data: 
The accompanying form should contain all relevant details pertaining to the patient.  
Clinical details are very important to the cytologist as this can explain the hormonal 
status, of the cells on the smear (e.g. atrophy in estrogen deficiency), blood (e.g. during 
menstruation), and the presence or absence of endometrial cells (e.g. pre- versus post 
menopause), (fig.4), infection, etc.  The patient’s age and contraceptives used, aids in 
correct interpretation of the cells on the smear (Marques and Mc Donald, 2000). 
 
 
 
 
 
 
 
Figure 4.  Example of cervical smear with isolated squamous cells and a group of                                                   
endometrial cells.  ?  Menstrual smear.  Three-dimensional cluster of endometrial cells. 
(Note – the blue cell with the vesicular nucleus is an intermediate type cell and the pink cell with a 
pyknotic nucleus is a superficial type cell – see page 10).   
                     (Taken from The Bethesda system for Reporting cervical cytology). 
 
1.1.5. Transportation of cervical smears: 
Timeous Cytoprep-fixation is the perfect “transport medium” for a conventional cervical 
smear and this fixation will keep the cells in perfect condition for a couple of days (SOP-
LP-PCYTO-013). 
 
1.1.6. Receiving the specimen in the laboratory: 
Training on the receipt of specimens in the laboratory is regarded as of utmost 
importance as NO mistake may be allowed here.  Only one specimen is opened at a time 
with its corresponding form.  The information on the slide is compared with those on the 
form, and if correct, the slide is assumed to belong to that form and both the slide and the 
accompanying form are allocated a unique laboratory number.  This number is also 
entered in the daybook and all the relevant data is written next to this number.  This slide 
is now ready to be stained (SOP-WI-PCYTO-001). 
 
1.1.7.   Staining of slides: 
Before any diagnosis can be made on any slide, the slide needs to be stained by various stains to enable the screener to interpret the 
cells with the aid of a microscope.  Laboratories vary in their way of staining cervical slides since some procedures are automated with 
different pre-set staining machines.  Other laboratories stain manually. 
 
The stain differentiates superficial from intermediate squamous cells and generally leaves 
mucin unstained. The main components of the stain are haematoxylin which stains the 
nuclei, and OG6 and EA65 which stain the cytoplasm. The cytoplasmic dyes behave as a 
trichrome stain which relies upon the interaction between the dye molecule size and 
tissue pore space.  The rationale of the stain is based on the fact that dye molecules are 
displaced by molecules of increasing size until the largest dye sits in the largest pore 
space. 
 
Quality control of staining of slides is of utmost importance and the quality of staining of 
every slide is commented on, on every worksheet. Corrective action is taken accordingly.  
The filtering of the contents of the staining dishes is also very important as this avoids 
contamination of one batch of smears by the other (SOP-WI-PCYTO-008). 
 
1.1.8.   Mounting: 
The slide is mounted manually with a mounting medium and a glass coverslip placed 
over the mounting medium to protect the smear and ensure that the slide can be kept for a 
long period of time. 
 
All stained slides are mounted under an extractor fan using the approved mounting 
medium, e.g., Entellan or DePex.  Cross-contamination (by touching the smear with the 
pipette and then applying the mounting medium onto another slide) and air-bubbles are 
avoided at all times – and also commented on, on every worksheet.  Take note that an air 
bubble can obscure an abnormal cell (SOP-WI-PCYTO-010).  Certain smears can have 
thicker areas where the smear has not been spreaded evenly.  It can then be difficult for 
the mounting medium to cover these thick areas.  This causes air-bubbles and the slide 
has to be remounted. 
By law, all abnormal smears must be retained permanently – therefore the quality of the 
mounting medium must also be assessed, as the quality of the staining has to be 
maintained for future reference.  Should the staining intensity fade, the slide can be 
placed in xylene until the coverslip comes loose and the mounting medium can be 
dissolved, and the slide restained for further use (SOP-WI-PCYTO-010). 
 
Most Cytology laboratories that evaluate high volumes of slides per week make use of an 
automated mounting machine.  These machines can mount up to 400 slides per hour and 
have different settings for the various sizes of coverslips used in that specific laboratory. 
 
The size of coverslips used is a very important component of quality assurance, as 
pathology laboratories do differ on the percentage of abnormal cells missed upon using a 
smaller coverslip (Oommen, et al., 1998).   
 
1.1.9.   Labelling: 
Every slide has to be labelled with a unique laboratory number stating clearly the current 
year and the department, e.g. 04CS00001 (04 for the year 2004, CS for the cytology 
department and 00001 being the numerical number).  This will enable the cytologists to 
retrieve slides in years to come.   
 
Before a slide is labelled, the name and number on the slide as well as the form is 
compared and the appropriate label is attached to the frosted end of the slide. This is the 
third quality assurance check which ensures that the slide has the correct name, number 
and label   (SOP-WI-PCYTO-013). 
 
1.1.10. Screening: 
Screening entails looking at every cell on the smear and evaluating the cells through a 
microscope.  Examination of the nucleus of the cell helps to diagnose abnormality and 
examination of the cytoplasm of the cell helps to interpret the exact origin of the cell. 
The normal cell-types that may be seen on a cervical smear sample may include epithelial 
cells from the ecto- and endocervix, the vagina and endometrium. In addition acute and 
chronic inflammatory cells, red blood cells and spermatozoa may be seen. 
Non-keratinised squamous cells reflect the hormonal status of the patient that will be 
related to her age, the use of hormonal contraceptives or hormonal replacement therapy, 
and the stage of her menstrual cycle. 
Superficial squamous cells are shed from a fully mature squamous epithelium, which has 
developed its full thickness under the influence of oestrogen and will be most numerous 
at the middle of the menstrual cycle. The cells stain pink with the Papanicolaou stain, are 
angular outline, 40-60 micrometers in diameter, and contain a shrunken hyperchromatic 
pyknotic nucleus. 
Intermediate cells are shed from the surface of semi-mature epithelia that shows a 
diminished response to oestrogen or the effects of progesterone and are commonly seen 
at the latter stages of the menstrual cycle, they are 30-60 micrometers in diameter, 
contain glycogen and stain blue/green with the Papanicolaou stain and contain a clearly 
defined round or oval vesicular nucleus 8 micrometers in diameter. 
Parabasal and basal cells are seen in the absence of either oestrogen or progesterone, and 
are found in pre-pubertal smears, post-menopausal smears or post-partum smears. The 
cells are small, 15 -20 micrometers in diameter, sometimes in syncitial sheets, with 
vesicular nuclei. They usually stain blue and contain a regular granular nucleus with an 
occasional chromocentre. Cells exfoliated spontaneously appear round whereas those 
detached with the spatula appear as sheets or have cytoplasmic processes. 
Squamous metaplastic cells arise when the columnar endocervical cells are exposed to 
the acid environment of the ectocervix. In response the reserve cells within the epithelium 
form squamous cells rather than columnar cells, the effect of which is to move the 
squamous-columnar junction towards the ectocervix. Immature squamous metaplastic 
cells show nuclear and cytoplasmic features of both columnar and squamous cells. It is 
during the process of transformation that the cells become susceptible to the HPV 
infection that may cause them to develop pre-malignant changes.  
The sample should be taken from the squamo-columnar junction and should contain both 
squamous cells and columnar cells from the ecto- and endocervix, squamous metaplastic 
cells may also be present (http://www.curran.pwp.blueyonder.co.uk). 
At the Ampath laboratory in Port Elizabeth, conventional cervical smears and normal manual light microscopy are used.  (Most 
laboratories in South Africa use conventional cervical smears and light microscopes).  With hundreds of thousands of cells on every 
slide, the screener depends heavily on quality assurance steps 1 to 9, as this will make her/his job easier! 
 
The slide is usually screened from the labelled side, up and down the width of the slide, 
to the end of the glass coverslip.  Every cell must be evaluated correctly and cautiously 
and reported on in a specific way acceptable and understandable by everybody 
concerned.  At this stage, the Bethesda System 2001 is in use.  This system has preferred 
nomenclature and recommendations (Apgar, et al., 2003). 
 
The screener checks on the previous records of every patient and any previous results or 
slides are retrieved for reviewing.  These findings are then compared to the current slide 
on this patient (SOP-WI-PCYTO-035). 
 
Any cell that is worrisome to the screener is marked with a permanent marker and 
marked as such at the bottom of the worksheet.  The slide and worksheet is then handed 
to the senior checker.  The slide is then rescreened by the checker and discussed with the 
screener.  An opinion is formulated and all abnormal slides are then presented to the 
pathologist in charge, after which a final diagnosis and recommendation is generated 
(SOP-WI-PCYTO-035). 
 
In the 1990s, it was in vogue to develop computers attached to the microscope, which 
would support the cytotechnologist with conventional microscopy.  The system 
connected sensors to the microscope stage to a computer and monitor display.  This 
provided a map of which areas of the slide had been screened, useful when training in 
microscopy techniques and in ensuring the complete screening of slides by 
cytotechnologists.  The device offered feedback to the cytologist and laboratory managers 
on screening techniques.  Quality control data including time spent per slide, percentage 
coverage of the slide surface and total workload was also collected and analyzed.  
Unfortunately these systems were costly and perceived as having only quality and 
cytotechnologist support value and have not been commercially successful.  Most are no 
longer developed (Gray and McKee, 2003). 
 
1.1.11.   Typing: 
The report is typed and handed to the pathologist.  All relevant data is rechecked before 
the result is signed off and ready to be printed.  This result is now ready to be posted or e-
mailed (SOP-WI-PHIST-500). 
 
1.1.12.   Re-check:  
Although the result is now ready and available to the referring clinician, (in our 
laboratory) EVERY smear is rescreened by the checker to ensure a 100% correct result. 
Once again the patient’s history is checked, and any possible previous reports retrieved 
and checked according to the current slide and follow-up recommended (SOP-WI-
PCYTO-035). 
 
If a recheck shows a difference in opinion, that slide and form is submitted to the 
pathologist in charge, discussed with the screener and monitored as such. Amendments 
and recommendations may be authorized by the pathologist in charge (Baker, et al., 
1995). 
 
When a result is signed off, the patient’s details, doctor’s details, clinical details, as well 
as the complete report are double checked as an extra quality assurance measure (SOP-
WI-PCYTO-035). 
 
1.1.13. Statistics: 
The statistics of every screener is monitored (Fig. 5).  This entails the number of slides 
screened by each individual screener per day as well as their percentage rate of 
agreements and disagreements.  Minor and major mistakes in screening are managed 
according to SOP-WI-PCYTO-037.  Minor mistakes are regarded as the misinterpretation 
of the presence or absence of endocervical cells, fungi, etc. resulting in no change to the 
management of the patient.  A major mistake is regarded as misinterpretation abnormal 
cells which results in a change to the management of this patient, e.g. for a diagnosis of 
LSIL the management of the patient is colposcopy, but for a diagnosis of HSIL (High 
grade squamous intra-epithelial lesion) the management of the patient is colposcopy as 
well as endocervical assessment.  Every cytology laboratory endeavours to a 100% 
accuracy rate, but unfortunately that is not always possible. 
0%
20%
40%
60%
80%
100%
Co
n
c
o
rd
a
n
c
e
 
ra
te
1st 2nd
screener
3rd
agree
minor disagree
major disagree
Figure 5:  Screener averages for the month of October 2004: 
               (Data taken from Ampath laboratory Port Elizabeth) 
 
The turnaround-time of all cytology specimens is monitored.  The acceptable turnaround-
time according to SANAS is 5 working days. The cytology laboratory at Ampath Port 
Elizabeth has a turnaround-time averaging 6 hours.  Turnaround-time is calculated as the 
time from where the specimen arrives in the laboratory, to the time the result is signed 
out and posted (pre-analytical, analytical and post-analytical phases). 
 
1.1.14. Comparison with histology specimen: 
In histopathology, disease states are diagnosed by studying stained tissue sections of 
biopsies, body tissue organs and the diagnosis are based on the pathologist’s acquired 
knowledge and experience (Fig. 6).  This can often lead to difference of opinion and 
assessment (Williams, et al., 2003).   
 
Despite this, histology is still regarded as the gold standard.  Similarly, in cytopathology 
diagnoses are made on stained smears and body fluids and the diagnosis is based on the 
cytotechnologist’s and pathologist’s acquired knowledge and experience.  This can also 
often lead to difference of opinion and assessment (own observation).   
 
All cervical biopsies are therefore checked for previous cervical smear results, and visa 
versa.  When the results differ, the appropriate action is taken by the pathologist and 
discussed with the submitting doctor (SOP- WI-PHIST-096). 
 
 
Figure 6: A slide prepared from a histology section.    
(Taken from The Bethesda system for reporting cervical cytology). 
 
Glandular and squamous lesions may coexist.  In figure 7, HSIL is seen on the squamous 
epithelial surface on the left side of the image, and the endocervical adenocarcinoma in 
situ is present in the gland spaces on the right.  (Adenocarcinoma in situ is a non-invasive 
high-grade neoplasm of glandular cells – a precursor to Adenocarcinoma). 
  
 
 
                                             
 
 
 
 
 
                                   Figure 7: Cervical smear taken from 42-year old woman.  (HSIL) 
                                    (Taken from The Bethesda system for reporting cervical cytology). 
 
Although uncommon, nucleoli may be seen in HSIL.  The chromatin appears less 
coarsely granular.   
 
Figures 6 and 7 shows the difference in screening a histology slide as opposed to a 
cytology slide.  Figure 6, the histology slide, shows the growth pattern of the cells.  
Figure 7, the cytology slide, shows the cells exfoliated or scraped off when the smear is 
taken.                                                                                     
 
 
1.2   Statement of the problem: 
The question arises whether we should aim to screen a greater percentage of women in South Africa or whether (taking the financial 
constraints into consideration) we should rather endeavour to increase the quality of every diagnosis on EVERY cervical smear on the 
41% of women we do receive.  
 
The question arises why patients present with advanced cervical disease ab initio in 
countries where cervical screening programs are available.  This is regarded as a failure 
of cervical smear screening. 
 
There are a variety of interrelated factors relating to failure of cervical smear screening, 
these include: 
 Patient –related factors: 
A large group of problems related to failure of cervical smear screening are patient –
related errors, including women who do not go for cervical smears at all or those that are 
loss to follow-up (Golden and Hickman, 2004). 
 
Other patient-related factors occur (Howe, 2003).  For example, douching or coitus may 
mechanically remove the superficial cell layers that the cervical smear samples, resulting 
in false-negative smears due to sampling errors. 
 
Patients may also delay seeking medical attention even when they have symptoms that 
they know are suspicious, such as abnormal vaginal bleeding (De Paula and Madeira, 
2003). 
In addition, many things known to be important risk factors are under the patient’s 
control, such as smoking, age at first intercourse, number of sexual partners and method 
of contraception (Karube, et al., 2004). 
 
Clinical errors: 
The next group of errors, unfortunately, comes from those who should “be informed,” the 
health care providers and clinicians.  Among the most common errors are failure to take 
cervical smears at all, or failure to take a representative cervical smear – a thinly spread, 
well-fixed smear containing both ecto- and endocervical component.  The smear must be 
taken under direct visualization and with considerable pressure. 
 
Failure of the clinician to provide pertinent clinical details may compromise cytological 
interpretation of the smear.  Other common clinical errors include failure to follow-up 
abnormal smears, failure to perform a biopsy of suspicious lesions, and failure to 
investigate suspicious clinical symptoms.  Unfortunately, it also seems likely that some 
clinicians accept a negative report at face value, disregarding statements of specimen 
adequacy.  Miscellaneous problems, such as clerical errors, also occur (De May, 1995). 
 
Cytopreparation and diagnostic errors: 
Errors in diagnosis can occur in relation to cytopreparation, screening, or interpretation, 
as well as to general laboratory problems, such as mislabelling slides. 
 
There are several points to be considered in assessing screening errors, i.e. failure to detect abnormal cells that are present on the slide.  
Three of the most common diagnostic problems relate to the presence of few abnormal cells, small abnormal cells and bland abnormal 
cells.  Other problems in interpretation include inflammatory changes, regeneration/repair, radiation effect, and atrophy.  Another 
diagnostic error is rendering a negative diagnosis on unsatisfactory material. 
 
There is also a class of cells that have been designated “litigation cells.”  (And with the filing of criminal charges in cases of cervical 
smear misdiagnoses, these cells may well  
become known as “jail cells.”)  Litigation cells are important sources of false negative as 
well as false-positive results.  The clinical significance of litigation cells ranges from 
completely benign to frankly malignant.  They are small, medium, or large cells, with 
low, intermediate, or high n/c (nuclear to cytoplasmic) ratios, smooth or irregular nuclear 
membranes, fine to coarse chromatin, which can range from pale to dark, and have 
inconspicuous to prominent nucleoli (De May, 1999). 
 
Lesion-related errors: 
For various reasons, some lesions fail to exfoliate cells in numbers sufficient for 
diagnosis (Gupta and Sodhani, 2004).  Small or inaccessible lesions may be difficult to 
sample adequately, and therefore false-negative cytology is more common in smaller 
lesions (Coldman, et al., 2003). 
 
Unfortunately, smears are more often inadequate in patients with severe epithelial 
abnormalities.  Necrosis, inflammation, or bleeding may obscure, alter or dilute the 
abnormal cells, making diagnosis difficult (De May, 1999). 
 
Rescreening and quality assurance in the laboratory is of utmost importance (Hadwin, 
2003). 
 
1.3   Objectives: 
 
As these are just some of the aspects of normal daily routine in cytology practice that can 
contribute to a far better abnormality pick up rate cytologically, the author has decided to 
take the information in the laboratory and prove the positive influence of proper quality 
assurance on correct diagnoses to which every patient is entitled.  The findings will 
involve many patients as an average of 4600 cases of cervical cancer was reported in 
2002.   
 
Taken that this figure only involves the 41% of women that go for cervical smears, the 
author was interested to know what the figure would be with proper quality assurance at 
all levels. 
 
The objectives are thus: 
• To determine whether the presence or absence of endocervical component has an 
effect on the adequacy of cervical smears 
• To determine the impact of using smaller coverslips on quality assurance 
• Evaluate the effect that re-screening of smears has on quality assurance in the 
cytology laboratory. 
 
1.4   Methodology 
The (n = +/- 61 000) cervical smears received in the laboratory since the year 2000 will 
be evaluated and re-evaluated with the above objectives in mind.  The slides will be 
retrieved from the archives of the Ampath laboratory in Port Elizabeth.    
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CHAPTER 2 
Literature overview 
 
 
 
 
2.1   Quality assurance in cytology:  an overview 
 
 
Over the last 15 years, cervical screening using the conventional cervical smear test has 
been introduced successfully in many countries of the world (Hudson, 1985).  Until the 
1990s, the accuracy of the cervical smear had rarely been questioned although its efficacy 
has never been tested in a prospective blinded trial.  The general public and most health 
care professionals failed to recognize the fundamental limitations of the cervical smear as 
a screening test and expect standards that even most diagnostic tests cannot achieve. 
 
If reductions in the incidence and mortality of cervical cancer are to be achieved, 
attention has to be focused on the screening test itself (Kurtycz, 2003).   Notwithstanding 
the effectiveness of the cervical smear, there is good evidence that the smear test is not 
sufficiently sensitive, specific, and consistent in reliably detecting the presence of 
cervical intra-epithelial neoplasia (CIN) in the cervix (Hoffman, et al., 2003). 
 
In the literature, the sensitivity of a single cervical smear is assessed at around 50-60% 
(Hoffman, et al., 2003).  This is perhaps not surprising since, unlike most other 
laboratory tests, the cervical smear methodology has remained essentially unchanged in 
over 60 years.   
 
The method of collecting and preparing a cervical sample has inherent limitations, 
therefore the high inadequate rates and low sensitivity can be overcome by repeating the 
test at regular intervals. 
 
 
 
 
The deficiencies of conventional cervical smears are due to many factors, including the 
use of wooden samplers that are cheap and designed to collect material from the cervix 
but are not flexible or designed to spread material evenly onto a glass slide (Fig. 11). 
 
The sampler used by the clinician is basically of his/her own choice, but the point of 
decision should be diagnostic accuracy rather than a high proportion of good quality 
smears. 
 
In addition to variable dexterity in collecting and preparing the sample, smear takers use 
a multiplicity of different fixatives in a variety of different ways.  Thus there are great 
variations in the quality of smears sent to the laboratory:  cellular distribution on the glass 
slide is uneven; cells may be obscured by blood or inflammatory exudate or thick streaks 
of other cells; total numbers of abnormal cells may be very few; fixation is variable and 
partial drying artefact is common, leading to poor staining and loss of microscopic detail.  
Not only do all of these influence the adequacy of the sample, they also limit the ability 
of the laboratory staff to interpret the cells present on the smear correctly.  Sometimes the 
result is just too few intact cells on the slide, particularly in the presence of atrophy or 
cytolysis, rendering it inadequate for assessment (Gray and McKee, 2003). 
 
It is worth noting that abnormal cells are not collected evenly on the sampling device and 
only a selected proportion of the cells are placed on the glass slide.  In fact, the amount of 
material transferred successfully to the glass slide ranges from around 60% at best, to less 
than 10% at worst and some samplers have more of a trapping effect than others. Thus, 
depending on the sampler used, up to 90% of the material scraped from the cervix may be 
discarded with the sampler (Apgar, et al., 2003).  
 
Furthermore material is transferred from the sampler to the slide in a non-randomized 
way and therefore the cellular material on the glass slide is spread unevenly. Abnormal 
cells may be present only in one small area, rather than evenly distributed across the 
slide.  Contrary to public belief, sampling and preparation together are responsible for 
about two-thirds of false negative results   (Gray and McKee, 2003). 
 
The low sensitivity of a single cervical smear is therefore mainly due to incorrect or 
inadequate sampling of the cervix; poor transfer of cells to the glass slide; sub-optimal 
preparation and fixation and only to a lesser extent, the microscopic assessment in the 
laboratory.  However, all of the above affect the ability of the cytotechnologist to identify 
abnormal cells on the slide.  Only a small proportion of all false negative tests are due to 
human error in microscopic assessment of the laboratory (Fig. 8).   
 
The following chart shows the difference in opinion of three qualified cytotechnologists. 
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Figure 8:  Difference in opinion of screeners for the year 2003 
(Data taken from averages of screener opinions for the year 2003 Ampath laboratory Port Elizabeth). 
 
The false positive cervical smear is far more prevalent and far more costly to the health-
care system and causes emotional stress for women. 
 
The move towards new technologies is driven by the need to improve these deficiencies 
in the current methods of cervical screening.  Improvements in diagnostic accuracy of the 
cervical smear need to begin in the doctor’s rooms with improved techniques of specimen 
collection to allow better quality samples and better slide preparations.  If a representative 
sample is not removed and sent to the laboratory, there is little that laboratory staff can do 
to improve the sensitivity of the test. 
 
Thus the quality of the sample sent to the laboratory, the presentation for microscopic 
assessment and the accuracy of the observer need to be addressed  (own observation). 
 
Quality assurance is of utmost importance. 
 
2.2   Accreditation:  literature review 
 
Although accreditation of medical laboratories was initiated in 1961, definite medical policies were not imposed globally and 
therefore the management of many medical laboratories still had the choice of being accredited or not in the 1990s!  Several 
newsletters emphasized the necessity of accreditation and quality assurance, but sometimes to no avail. 
 
Two distinct systems of total quality management applicable to medical laboratories 
exist:  accreditation and certification. According to the ISO/IEC guide, by definition, 
‘accreditation’ is a procedure by which an authoritative body gives formal recognition 
that a body or person is competent to carry out specific tasks.  On the contrary, 
‘certification’ is a procedure by which a third party gives written assurance that a 
product, process or service conforms to a specific requirement.  In common usage to 
‘accredit’ means to certify or guarantee someone or something as meeting required 
standards and to ‘certify’ means to endorse or guarantee that certain required standards 
have been met (Linko, 2003). 
 
Globally, the organizations accrediting or certifying medical laboratories are of different 
types, i.e. governmental or authoritative organizations.  The development of laboratory 
accreditation started, as it became clear to the United States Congress that unsatisfactory 
testing was performed within health care sectors.  Consequently, the College of American 
Pathologists (CAP) initiated the first accreditation scheme in 1961 specially designed for 
medical laboratories:  the Laboratory Accreditation Program (LAP).  Today, the CAP 
program is recognized by the Joint Commission on Accreditation of Healthcare 
Organizations (JCAHO) and has a decision authority under the Clinical Laboratory 
Amendments of 1988 (Roberts, et al., 1987). 
 
In Australia the National Association of Testing Authorities (NATA) as a principal 
inspection agency, has experience with accreditation for over 50 years mainly for the 
benefit of Australian industry, government and the community.  A medical testing 
program 
was established by NATA in 1983 to accredit pathology facilities.  The Australian 
principles of accreditation follow the ISO 9000 standard series and ISO/IEC Guide 25.  
The Canadian Council on Health Service Accreditation (CCHSA) introduced a Client 
Centered Accreditation program in 1995 focusing on the implementation of Total Quality 
Management in medical laboratories. 
 To demonstrate the required procedures, European medical laboratories started to take 
action during the 1990s in developing their quality systems.  The first medical 
laboratories were accredited in Sweden in 1992 by SWEDAC, the Swedish accreditation 
body (Linko, 2003).  Since then, the number of accredited laboratories, representing 
disciplines of clinical chemistry, clinical microbiology, blood banking and pathology has 
been growing exponentially in the Nordic countries.  Today, more than twenty medical 
laboratories in Finland have fulfilled the accreditation requirements assessed by FINAS, 
the Finnish Accreditation Service.  In the United Kingdom, medical laboratories follow 
the national standards set by the Clinical Pathology Accreditation (CPA), which serves 
also as the national accreditation body (http://www.cpa-uk.co.uk). 
 
In addition to analytical issues, guidance for documenting and implementing some 
special actions has been taken in account.  These actions include, e.g. internal audits, an 
important management tool which medical laboratories might not have been so familiar 
with before (Linko, 2003). 
 
The new international standard ISO/IEC 17025 replaced the criteria of the EN 45001 and 
ISO/IEC Guide 25 standards for laboratory accreditation by the end of 2002.   
 
Mentioned below, are some medico-legal cases that were initiated in various countries 
where the laboratories concerned had to prove their quality management and assurance in 
courts of law: 
 
Between 1993 and 1994 there were three incidents in Australia and the United Kingdom 
of laboratories causing a failure in a cervical screening program by under-reporting 
cervical cytology. The Cervical Screening Advisory Committee brought these screening 
failures to the attention of the National Coordinator of the Program and the Ministry of 
Health.  Quality assurance policies had to be revised and implemented as a matter of 
urgency.  (Literature does not confirm the dates of accreditation of these laboratories). 
 
In June 1994, a hospital pathologist at Goodhealth Wanganui was found to have misread 
biopsy specimens.  The pathologist was 62 years of age and had been diagnosed with 
Parkinson ’s disease in late 1993.  A review of his work revealed that he did not 
participate in quality assurance activities; he did not participate in continuing medical 
education and he was working in an isolated environment.  It was recognized that all of 
these circumstances may have impaired his work as pathologist.  The Cervical Screening 
Advisory Committee had to once again revise and implement various quality assurance 
requirements. 
 
A newsletter of January/February 1993 contains an article on the accuracy of smear tests of 237 women referred to the Royal Hospital 
of Women in Sydney for invasive cervical cancer.  The article noted that a worrying aspect was the number of patients whose previous 
smears on review, showed frankly malignant cells but were originally reported as normal. 
 
In a second newsletter of March/April 1994, there is an article on a screening failure in Great Britain which described how a group of 
2 000 women were recalled in Grennock where smears had been wrongly read for five years in a laboratory described as understaffed, 
antiquated and isolated.  The Advisory Committee advised the national coordinator that appropriate quality assurance is mandatory. 
 
During 1991, a Ministerial inquiry was initiated into the under-reporting of cervical smear abnormalities in the Gisborne region.  It 
was found that the pathologist was the only primary cytology screener and that the laboratory only received approximately 4000– 
5000 
cervical smear tests per annum.  There was inadequate internal quality control as the pathologist did a 10% re-screen once a week and 
also had no other medical professional to consult with.  The pathologist also did not compare the re-read results with the original 
results. There was also no correlation of biopsy results with cytology results and no external quality assurance program.  The 
laboratory was not accredited with an independent quality control authority and the pathologist participated very rarely in continuing 
medical education.  Even though the accreditation requirements for the Testing Laboratory Registration Council (TELARC) were not 
as demanding in the early 1990s as they are now, they still would have deterred this pathologist from practicing as he did.  Most 
importantly, from 1993 onwards, as long as Gisborne Laboratories employed only one person to carry out all cervical cytology, it 
would have been denied accreditation (Ministerial inquiry, 1991). 
 
Factors relating to the delivery of cytological services in New Zealand between 1990 and March 1996: 
From the years 1990 to 1996 cytological services in New Zealand were delivered in circumstances where: 
 
- Laboratories reading cervical cytology were not required to follow quality control processes or to be accredited with an independent 
quality control authority; 
 
- The Government Policy for National Cervical Screening (1991) and the 1993 updated version in relation to laboratories reading 
cervical cytology were not well designed; 
 
- The National Cervical Screening Register was not functioning optimally; 
 
- There were no performance standards for laboratories, and there were no reliable data on laboratories’ performance; 
 
- There was no monitoring and evaluation of the performance of laboratories reading cervical cytology; 
 
- The health authorities did not take heed of the warnings provided by the failures of cervical screening laboratories in other countries; 
 - There was a failure to ensure all components of the program were in place from an early stage. 
 
- Compulsory accreditation for all cytology laboratories was not introduced until late 1996.  It is difficult to be precise about when 
these requirements were introduced, as their introduction into individual laboratories was achieved at different times and through more 
than one mechanism.  It is clear that before this time, accreditation and quality assurance was not mandatory, even though the need for 
quality assurance of cytology laboratories was seen as essential by more than one authoritative source from as early as the mid-
eighties (Ministerial inquiry, 1991). 
 
Similar situations occurred globally and accreditation and quality assurance became compulsory for all laboratories, within a certain 
time limit. 
 
Accreditation authorities had to learn from the above experiences and had to implement 
quality assurance programs that ensure that each laboratory maintains the highest level of 
performance and quality assurance. 
 
South Africa is now firmly part of the global market place and globalization increases the need for local accreditation and associated 
systems that are accepted internationally.  Already many countries’ national accreditation bodies, such as SANAS in South Africa, 
have come together to create an international platform.  International Laboratory Accreditation Cooperation (ILAC) focuses on 
laboratories and inspection.  It has over 60 members (http://www.sanas.co.za).   
 
In November 2000, ILAC formalized an international Mutual Recognition Arrangement amongst 36 of its members who had been 
successfully evaluated for compliance with pre-agreed criteria for competent operation of laboratory accreditation programs.  SANAS 
was among the founder members of this arrangement. 
 
The International Accreditation Forum (IAF) focuses on certification and also inspection.  It has 25 members and at the moment 
focuses primarily on quality management certification.  As a member of IAF and ILAC, SANAS represents South Africa in all matters 
related to accreditation in conformity assessment (http://www.sanas.co.za). 
 
The Ampath laboratory in Port Elizabeth was successfully accredited in November 2001.  
The South African National Accreditation Society (SANAS) accredits various 
laboratories with the view of accrediting all South-African laboratories within a certain 
time limit.   
 
The accredited laboratories have to uphold a very high standard of quality to remain 
accredited.  Teams of professionals inspect the laboratory every 2 years and other quality 
assurance staff inspects the laboratories every few months.   
 
2.3 Accreditation procedure: 
 
To have a laboratory accredited, entails a lot of hard work, preparing standard operating 
procedures and it is a very nerve-racking experience when the team of specialists from 
SANAS comes personally to the laboratory and inspects every department. 
 
They do a very thorough check of various facets of the company, namely: 
 
2.3.1   The organization and Management 
1.  The laboratory’s practice number and registration number has to be displayed.  
No temporary or mobile facilities are allowed. 
2. A detailed organogram as well as a clearly defined technical managerial 
hierarchical structure of the entire management has to be clearly displayed in the 
laboratory. 
 
2.3.2    Quality management 
1. Regional as well as departmental quality policies and manuals have to be 
readily available and updated at all times.  
 
2. SHE policies and procedures.  (These policies and procedures are reviewed 
annually and amended accordingly.  Should law alter the policy for sick leave, the 
appropriate policy should be amended immediately). 
3.  All new methods and equipment evaluated and/or reviewed and documented 
accordingly.  (Should the method of staining a slide be altered, the standard 
operating procedure should be changed accordingly). 
 
2.3.3   Personnel 
           Each member of staff has his/her own personnel file with the following: 
1.  Curriculum vitae 
2.    Detailed job description 
3.  Current registration certificate with HPCSA (if necessary) 
4.  Health record 
5.  Detailed training record 
6.  Disciplinary actions and warnings 
7.  In-house work experience record 
8.  Attendance register of all meetings and seminars attended 
 
2.3.4   Specimen collection 
1. Various SOPs for specimen collection, storage, handling of specimens and 
safety precautions have to be in place and readily available in the laboratory 
2.  A SOP for labelling of specimens has to be in place. 
3.  A SOP describing the appropriate transport medium has to be available. 
4.  Preparation of the patient prior to specimen collection has to be documented 
on the specified form.   
5.  Documented instructions are needed for special storage arrangements of 
specimens.  
6.  Precautions should be taken with specimens that are damaged and unsuitable. 
7.  Safekeeping of all records is very important, as abnormal results should be 
kept forever and normal results for at least 10 years. 
 
 
2.3.5   Specimen request form 
The following details are required on this form: 
 1.  Time and date of taking specimen 
 2.  Name, address and/or location of hospital 
 3.  Age and gender of patient 
 4.  Name of the health professional requesting the test 
 5.  Minimum relevant clinical data for the test 
 6.  Date and time specimen arrives in laboratory 
 
2.3.6   Specimen reception 
SOPs are required for the following procedures: 
 1.  Handling of specimens in reception area 
 2.  Documented method of reception 
 3.  Documented protective measures 
 4.  Handling of urgent specimens 
 5.  Handling of specimens after hours 
 
2.3.7   Specimen identification 
SOPs are required mentioning all the following procedures: 
 1.  Unique identification number for each specimen 
 2.  Identification number quoted on all documentation pertaining to this specimen 
 3.  Laboratory policy for handling and/or rejection of unsuitable specimens or 
      Inadequately labelled samples 
4. Documented procedure for recording dispatch and receipt of referred 
     specimens to and from laboratory 
 
2.3.8  Test methods 
SOPs are required with all the following details: 
1.  Validation of test methods recorded 
2.  Detailed step by step instructions for each test procedure 
3.  Principle of method 
4.  Storage and preparation of materials 
5.  Calculations and calibrations controlled and recorded    
 6.  Identification of potentially hazardous operations or materials 
 7.  Signature of person who checked and authorized method for use 
 
2.3.9    Quality assurance programme 
Each laboratory should have an updated copy of the following: 
1. Written quality assurance programme / policy 
 2.  In-house safety guidelines 
 3.  Policy regarding hazards 
 4.  Safety of staff and testing personnel 
 
2.3.10   Test reports 
Each test report should contain the following: 
1.  Patient’s name, address and hospital number 
2.  Name and address of clinician requesting the test 
3.  Laboratory accession number 
4.  Date and time of collection  
5.  Name and location of laboratory performing the test 
6.  References to the tests requested 
7.  Clear and concise results 
8.  Date and time of issue of report 
9. Signature and title of person taking responsibility for content of result. 
 
2.3.11   Records 
     All records are checked to see whether the following rules are adhered to: 
            1.  Identify person performing the work 
            2.  Alterations signed and dated by authorized person 
            3.  Documented procedures to minimize transcription errors 
            4.  All records kept according to guidelines of Royal College of pathologists – 
                 Retention and storage of pathological records and archives 
5. Records kept in suitable filing system 
6. Patient data and reports only reported to the referring practitioner 
7. Records of all equipment, e.g.  Manufacturer, date received, current location, 
service planner, non-conformance list etc. 
 
2.3.12    Safety and fire 
 The safety officer keeps strict control on the following: 
            1.  Records and monthly feedback 
            2.  Documented fire drills 
 
2.3.13   Customer services  
1. Customer services 
2. Is a questionnaire available for doctor/client completion 
3. Were pathologists and science/technical personnel available to the 
doctor/client 
 
These are some of the facets of laboratory work that SANAS ensures are kept in place at all times by all Accredited laboratories! 
 
 
2.4 Specific contributing factors affecting quality assurance in 
the diagnosis of cervical smears: 
 
With the above as background, discussion will be directed to the following factors: 
 
2.4.1   The taking of the smear: 
As discussed before, the taking of the smears forms the most integral part of quality 
assurance.  Formal training in smear taking is essential if the cervical smear test is to be 
reliable and such training is increasingly available.   With the patient in the lithotomy 
position, the clinician should visually inspect the cervix and identify the transformation 
zone.   
 
 
 
 
Then, if possible, sampling should be directed to encompass the entire area, including 
both the endocervix and ectocervix.  
 Diagram 1:  Anatomy of female genital tract (Taken from Diagnostic pathology) 
 
The point at which the ectocervical squamous mucosa meets columnar cell mucinous 
epithelium of the endocervix is the squamocolumnar junction (Diag. 1).  This point is not 
static and moves proximally through the transformation zone as inflammation, infection, 
or other irritations necessitate that the distal canal be lined by a heartier squamous 
epithelium.  It can then recede when conditions normalize (Fig. 9).  Thus, the concept of a 
zone rather than a junction seems clear (Geisinger, 2003). 
 
 
Figure 9: Example of an opened cervix and uterus 
(Data taken from Ampath laboratory Port Elizabeth) 
 
As a quality measure, the proportion of inadequate or unsatisfactory smears in relation to 
the entire smear workload of a laboratory provides a valuable indication of the standard 
of reporting and of the level of expertise of the smear takers (Valenzuela, et al., 2001). 
 
2.4.1.1   Criteria for assessing smear quality: 
The question of adequacy of cervical smears is central to the success of cervical 
screening in the prevention of cervical cancer deaths.  The problem of establishing 
exactly what constitutes an adequate sample has received increasing attention in recent 
years, culminating in broad guidelines from various sources.  According to the Bethesda 
system, 8000 to 12000 well-preserved and well-visualized squamous cells plus 2 groups 
of at least 5 endocervical cells or squamous metaplastic cells is acceptable as adequate.  
Because the primary purpose for a cervical test is identification of squamous lesions, this 
is directed to these cells.  It is important to note that cell-by-cell counting has not been 
recommended, indicating that the cell number is to be estimated (Geisinger, 2003). 
 
The method for estimating cellularity has not been fully developed.  Some inherent smear 
characteristics might be expected to contribute to variations in apparent cell numbers, e.g. 
cytolysis, relative cell crowding, atrophic smears, mucus, inflammatory cells.  Given 
these confounding visual factors, the difficulty and subjectiveness involved in cell 
number estimation, becomes clear.  The proposed solution is comparison of the slide in 
question with reference images derived from smears showing various well-quantified 
levels of squamous cellularity. 
 
It seems logical to expect that, when looking at a number of fields on a conventional 
smear with questionable cellularity, these fields are likely to differ considerably from one 
another.  Thus the cytologist may be in the position of testing several fields, perhaps 
against a number of different reference images and then mentally calculating a quasi-
arithmetic sum of several subjective assessments.  The reproducibility of this method 
remains to be investigated (Geisinger, 2003). 
 
Atrophic smears (fig. 10) differ from the smears of younger women and therefore it is 
important for the screener to know the patient’s age and menstrual status and of any 
hormonal treatment.  (Atrophic smears show mainly parabasal cells and some 
intermediate cells due to low estrogen and the smear from a younger woman shows 
mainly superficial cells and intermediate cells due to higher estrogen effect). 
 
 
                                    Figure 10:  Atrophic smear – mainly parabasal cells 
                                  (Taken from The Bethesda System for reporting cervical cytology) 
      
As a working principle, cervical smears should consist of clearly displayed cellular 
material covering at least one third of the area under the coverslip, and preferably over 
one half.  The medical professionals combine ecto- and endocervical smears on one slide 
to save the patient the extra expense.  The mere inclusion of columnar or metaplastic 
cells, or both, does not necessarily confirm that the entire circumference of the 
transformation zone has been sampled.  The clinician taking the smear has to be relied 
upon for confirming the thoroughness of the sampling procedure.  Squamous cells of 
cervical origin are usually distributed in loosely cohesive streaks along the lines of spread 
of the smear. 
 
Whether smears without any endocervical cells or recognizable metaplastic cells should 
be accepted as representative, is debatable. The presence of these cells is determined 
largely by the position of the squamocolumnar junction and the state of maturation of the 
transformation zone, factors that are hormone dependent.  Thus it may not always be 
possible to include endocervical cells or identify metaplastic cells at all times.  An 
additional factor is the nature of the sampling device, the Aylesbury spatula giving a 
greater yield from within the canal than the Ayre spatula.  Brushes and broom devices 
provide the largest endocervical component.  There are many reports of comparative 
trials of the different smear taking instruments, the general conclusion being that devices 
with an extended arm give a more representative sample and have a greater likelihood of 
including abnormalities(Fig.11).  
 
        Figure 11:  Various spatulas used for taking cervical smears 
(The Ayre spatula second from left, the Aylesbury spatula far left and brushes and broom-like devices far 
right.)  (Taken from Gray and McKee, 2003). 
In a study of 635 patients with previous abnormal cytology referred to colposcopy, Henry 
and Solomon (1995) examined the effect of the amount of endocervical component on 
the detection of squamous lesions.   
 
The presence of one to five endocervical cell clusters increased the number of HSIL cases 
detected from 6% to 10%.  The presence of greater numbers of endocervical cells had no 
additional effect on the detection rate of HSIL.  Interestingly, the presence of 
endocervical cells did not affect the detection rate of LSIL (Low Grade squamous 
intraepithelial lesions).  In fact, large numbers of endocervical cells actually decreased 
the rate of detection of LSIL from 21% when one to five clusters were present, to 10% 
when greater than 25 cell clusters per slide were present.  This may be a reflection of 
sampling too far up into the endocervix, thus missing lower grade lesions which are more 
commonly found on the ectocervix (Apgar,et al., 2003). 
 
An excess of leucocytes obscuring epithelial cells (Fig. 12) may require investigation for 
a treatable cause, especially if a discharge is present.  Similarly, unsatisfactory smears 
taken postnatally should be repeated when normal menstrual cycles are re-established 
(Gray and McKee, 2003). 
 
 
Figure 12:  An example of an unsatisfactory cervical smear 
 (Note - no well-visualized cells could be identified due to obscuring white blood cells).                        
(Taken from The Bethesda system for Reporting cervical cytology).                  
 
Blood–stained smears are often poorly fixed or obscured by the blood (Fig. 13).  Contact 
bleeding on smear taking may be due to an ectropion, requiring treatment before a 
satisfactory smear can be obtained.  The epithelial cells are sometimes so obscured, that a 
definite diagnosis is not possible (Apgar, et al., 2003). 
 
Figure 13:  An example of a cervical smear obscured by red blood cells.   
(Note - If   50% - 75% of the epithelial cells are covered, obscuring red blood cells should be mentioned in 
the quality indicators of the report).  
(Taken from The Bethesda system for Reporting cervical cytology). 
 
Post-menopausal atrophy leads to scanty or inflamed smears, often with no endocervical 
cells.  The threshold of acceptance of smears from these women must be adjusted, but if 
there is cause to doubt the adequacy of sampling, a short course of local estrogen cream 
prior to smear taking usually ensures better sampling (Gray and McKee, 2003). 
 
 
2.4.2   Fixation of smear: 
Rapid fixation is essential to ensure the cells are well preserved.  Fixatives are applied to 
a smear or by immersion of the slide into a liquid.  The liquid fixatives include 95% 
alcohol, polyethylene glycol and/or carbowax.  The 95% alcohol is inexpensive, readily 
available and provides excellent cytological detail.  Its only disadvantages are the need to 
store and transport unstained slides in a container of liquid and to have the fluid and the 
containers at hand at the clinics or doctor’s rooms (SOP-LP-PCYTO-013). 
 
The alternative to wet fixation is the use of commercially available spray fixatives.  
These generally consist of various mixtures containing ethanol or isopropyl alcohol with 
carbowax (polyethylene glycol).  The latter leaves a coating on the slide after the alcohol 
has evaporated and is said to prevent cell shrinkage. 
 
Such sprayed slides are dry within a few seconds and are then suitable for storage, 
mailing, or immediate processing.  These coating fixatives must first be removed with a 
soak in 95% alcohol before staining is performed.  If this step is hastened, poor staining 
quality results. 
 
Aerosols expand isentropically when sprayed and thus are very cold.  If the spray is held 
closer to the smear surface rather than about 25cm from it, the cells become rapidly 
frozen and severely damaged.  The microscopic result often renders the material 
unsuitable for cytological examination  (Geisinger, 2003). 
 
Regardless of the fixative selected, it must be applied quickly because good results are 
obtained only if it is applied within a few seconds of making a smear. Severe drying 
effect renders cervical smears unsuitable for interpretation  (Geisinger, 2003).   
 
 
2.4.3   Marking of the slide: 
The slide should immediately be marked on the frosted end of the slide with a pencil or 
diamond pen.  The patient’s surname or the exact site of the smear taken should be 
written here thus preventing slides being mixed up with other patient’s forms, resulting in 
the incorrect slide being screened with the incorrect form.  When the clinician decides to 
take two smears, the slides should also be marked accordingly. 
 
Most clinicians do not follow this rule, but wrap the slide in its corresponding request 
form and put an elastic band around it.  The laboratory assistant then opens these slides 
one by one and marks the slides personally according to the name on the appropriate 
form wrapped around it  (SOP-WI-PCYTO-001). 
 
 
2.4.4   Submission of clinical data: 
Laboratory test results are of limited use in the absence of corresponding clinical 
information.  The range of necessary and pertinent information is broad but may range 
from only the patient’s age to complete information inclusive of the clinical history and 
physical examination for proper interpretation of a test result (Fig. 14). 
 
 
Clinical information is critical for the technologists, pathologists and clinicians alike with 
the ultimate goal of optimal patient care (Marques and Mc Donald, 2000). 
 
 
 
                         Figure 14:  Reactive changes – no clinical data  
                                                           (Could have been mistaken for abnormal cells)   
                                    (Taken from the Bethesda system for reporting cervical cytology) 
 
 
2.4.5   Transportation of cervical smears: 
Timeous Cytoprep-fixation is the perfect “transport medium” for a cervical smear and 
this fixation will keep the cells in perfect condition for a couple of days.  No ice packs or 
additional transport medium is needed (SOP-LP-PCYTO-013). 
 
 
2.4.6   Receiving of smear in the laboratory: 
Training on the receipt of specimens in the laboratory is regarded as of utmost 
importance as NO mistakes may be allowed here.  Only one specimen is opened at a time 
with its corresponding form.  The information on the slide is compared with those on the 
form, and if correct, the slide is assumed to belong to that form and both the slide and the 
form are allocated a unique laboratory number.  This number is also entered into the 
daybook and all relevant data written next to this number. 
 
If the slide is unmarked but individually wrapped in its particular requisition form, the 
name of the patient and the laboratory number is written on the frosted end of the slide 
and a note is written on the accompanying form that there was no name written on the 
slide. 
 
The particular sender is phoned immediately should there be any discrepancy as to 
whether the slide belongs to the form, or if the names differ.  Unless the clinician’s rooms 
can rectify this problem telephonically, the smear and form is returned to the rooms to be 
rectified (SOP-WI-PCYTO-001). 
 
 
2.4.7   Staining of slides: 
Laboratories vary in their way of staining cervical smears as some laboratories have 
automated staining machines with different pre-set staining times (Table 1).  Other 
laboratories stain manually, but in both cases the normal Haematoxylin – Eosin Pap stain 
is usually used. 
 
Quality control of the stained slides is of utmost importance and the quality of the 
staining of every slide is documented on every individual worksheet.  Corrective action is 
taken accordingly. (Should there be a batch of a certain stain or other chemical that is 
faulty, it should be replaced before the next slides are stained). 
  
The filtering of the contents of the staining dishes is also very important as this avoids 
contamination from one batch of smears to the next (SOP-WI-PCYTO-008). 
 
The slides are first placed in a dish with 95% alcohol to dissolve the carbowax of the 
fixative used by the clinician.  As Haematoxylin is a water based stain, the cells would 
fall off the slides if they were directly placed in this stain.   
 
Placement in 80% alcohol, 70% alcohol, 50% alcohol and then water hydrates the 
smears.  The cells are now hydrated and can be placed in the Haematoxylin stain. 
Haematoxylin stains mainly the nuclei of the cells.  Scott’s solution is used as blueing 
agent and then the smears are dehydrated again as the OG6 and EA65 stains are alcohol 
based and stain the cytoplasm of the cells.  
 
The dishes with the slide racks are thus placed into 50% alcohol, 70% alcohol and then 
80% alcohol to eventually get to 95% alcohol (methanol).   
 
The cytoplasm of the cells are stained with the OG6 and EA65 stains and washed in 
methanol.   
 
Before the slides can be placed in xylene – a clearing agent, a mixture of 50% methanol 
and 50% xylene is used, as xylene is oil based. 
 
The slide rack is then placed in the xylene for +/- 5 minutes to clear.   
 
The slides are not to be removed from the xylene prior to mounting (SOP-WI-PCYTO-
008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1:  Papanicolaou staining method  (Taken from SOP-WI-PCYTO-008) 
 
 
PROCEDURE: 
  
1 95% Alcohol 5 minutes        (fix smear and dissolve carbowax)       
2 70% Alcohol 10 seconds      (hydrate smear) 
3 50% Alcohol 10 seconds 
4 Water 20 seconds 
5 Haematoxylin 6 minutes         (water base – stain nuclei of cells) 
6 Water 10 seconds 
7 Scott's 2 minutes         (blueing agent) 
8 Water 10 seconds 
9 Water 10 seconds 
10 50% Alcohol 20 seconds       (dehydrate smear) 
11 70% Alcohol 20 seconds 
12 80% Alcohol 20 seconds 
13 Methanol 20 seconds       (95% alcohol) 
14 OG6 2 minutes         (alcohol-based dye – stains cytoplasm) 
15 Methanol 20 seconds 
16 Methanol 20 seconds 
17 EA65 2 minutes         (alcohol-based dye – stains cytoplasm) 
18 Methanol 20 seconds 
19 Methanol 20 seconds 
20 Methanol 20 seconds 
21 Methanol / Xylene 20 seconds 
22 Xylene 20 seconds        (clearing agent) 
23 Xylene 20 seconds 
24 Xylene 5 minutes 
 
 
 
The smears are now ready to be mounted with appropriate mounting medium. 
 
 
 
2.4.8   Mounting of slides: 
Since xylene is a known carcinogen, all mounting of slides should be done under an 
extractor fan.  Entellan of DePex can be used as a mounting medium.  Cross-
contamination (cells from the previous staining batch picked up by the slides of the next 
batch) and air-bubbles are avoided at all times since an air bubble can obscure abnormal 
cells (Fig. 15).  Cross contamination is avoided by filtering the contents of all the staining 
dishes.   
 
As the cervical smears have different areas of smear thickness, the mounting medium 
sometimes do not cover the thick areas and therefore form air-bubbles.  The slide is then 
placed back into a jar with xylene until the coverslip loosens and the slide can be 
remounted.  Then only can the slide be screened. 
 
The quality of the mounting of every slide is documented on every individual worksheet 
and corrective action taken if necessary  (SOP-WI-PCYTO-010). 
 
Figure 15:  Mounting of slides 
(Taken from Ampath laboratory Port Elizabeth) 
 
 
 
By law, all abnormal smears must be retained indefinitely – therefore the quality of the 
mounting medium must also be assessed, since the quality of the staining must be 
 
 
maintained for future referral to the slide.  If need be, the slide can be placed in xylene to 
remove the coverslip and then the smear can be restained as required. 
 
The size of the coverslips used is a very important component of quality assurance.  
Pathology laboratories differ in opinion on the percentage of abnormal cells missed when 
using smaller coverslips  (Oommen, et al., 1998).  There is a very big variety of 
coverslips – varying sizes and some are round, others are made of glass and others of 
plastic.    
 
The patient is entitled to an as thorough as possible evaluation of the smear evaluated and 
therefore the author’s laboratory agrees on using the larger coverslip (24mm x 50mm). 
 
 
2.4.9   Labelling: 
Before a slide is labelled, the name and number on the slide as well as the form is 
compared and the appropriate label is attached to the frosted end of the slide.  This is the 
third quality assurance check ensuring the slide has the correct name, number, label and 
accompanying form (SOP-WI-PCYTO-013). 
 
 
2.4.10  Screening: 
 
2.4.10.1   Manual screening: 
When properly obtained and prepared, cervical smears alert practitioners to possible 
abnormalities of the cervix.   
 
Manual microscopic screening of cervical smears by cytotechnologists continues to be 
the most widely used and accepted method of identifying irregular cells on cellular 
abnormalities of the cervix (Cronje, 2004).   
 
During manual screening of the cervical smear samples, cytotechnologists search for 
what may be a few abnormal cells by inspecting many fields on a slide under the 
microscope.   
Cytotechnologists must manipulate the microscope stage through visual inspection of 
approximately 50 000 to 300 000 epithelial and inflammatory cells per smear (De Palo, 
2004). 
 
Manual screening can be tedious and time-consuming since the majority of cells on the 
smear are normal.  Even smears with serious abnormalities may contain only a few dozen 
malignant or premalignant cells among hundreds of thousands of normal cells. 
 
The screener checks on the previous records of every patient and any previous results or 
slides are retrieved for reviewing.  These findings are then compared to the current slide 
on this patient (SOP-WI-PCYTO-032). 
 
Any cell that is worrisome to the screener is marked with a permanent marker and 
marked as such at the bottom of the worksheet.  The presence of transformation zone 
cells is also marked on the coverslip with a “T”.  The slide and worksheet is then handed 
to the senior checker. 
 
This slide is rescreened and discussed with the particular screener.  An opinion is 
formulated and the slide then may still be shown to the pathologist in charge  (Freckelton, 
2003). 
 
False-negative cervical smears: 
A false-negative cervical smear is defined as a normal cytological report of a woman with 
existing dysplasia, premalignant or malignant lesions of the cervix.  When these cells are 
missed, it results in delayed diagnosis that can lead to progression of the disease and the 
need for more aggressive treatment (Geisinger, 2003).  
 
False negatives can occur under the following conditions: 
  
 
 
Cell sampling and preparation: 
Accuracy of cervical smear results depends in part upon how well the cervical material is 
sampled and slides prepared.  At the time of collection, samples of cells collected from 
the surface of the cervix must contain both ectocervical and endocervical cells.  If 
abnormal cells are not included in the sample, abnormalities cannot be detected.   
 
False negative results can also occur if blood, vaginal secretions, or inflammatory cells in 
the sample conceal the abnormal cells making them undetectable by the human eye. 
 
 
Screening and interpretation: 
False-negative results, due to screening, are caused by failure to identify a relatively 
small number of abnormal cells in the screening process.  A trained cytotechnologist 
typically searches hundreds of thousands of cells per smear on up to 70 slides per day  
(SAMHSA TIPs 2004). 
 
Factors that may make a smear more likely to receive a false-negative 
interpretation: 
Few abnormal cells present 
Abnormal cells present on only part of a conventional smear 
Abnormal cells present singly rather than in groups 
HSIL cells that is small 
HSIL cells that lack nuclear hyperchromasia 
 
 
QUALITY ASSURANCE IS THEREFORE THE KEYWORD FOR EVERY 
CYTOLOGY LABORATORY. 
 With hundreds of thousands of cells on every slide, the screener depends heavily on 
quality 
assurance steps 1 to 9, as this will make his/her job much easier.  
 
Liquid-based preparations: 
There is a worldwide shortage of trained cytotechnologists and cytopathologists and the 
situation in the UK has currently reached crisis point.  There is much anecdotal evidence 
that liquid-based preparations are very popular with cytotechnologists.   
Liquid based cytology, or thin layer cytology, is a technique of preparing a monolayer of 
cells on a glass slide. The technique involves suspending the sample in a solution that is 
both mucolytic and haemolytic. The sample is concentrated either by centrifugation or by 
filtration.  In the former method a monolayer of cells sediments onto the slide, in the 
filtration method a monolayer of cells is pressed onto the slide from the filter. 
The clarity of the presentation, the improved cell preservation and lack of overlapping by 
other cells, blood and inflammatory exudates are much appreciated.  Depositing a 
representative sample on a discreet small area of the glass slide allows faster and more 
reliable assessment by laboratory staff.  The cells are in a predetermined smaller area on 
the slide and are mainly in one focus plane when using the x 10 screening objective.   
 
However, before a laboratory converts a cervical cytology service to liquid-based 
cytology, serious consideration must be given to some important issues.  Smear takers 
must use a broom-style plastic sample collection device.   
 
Smear taker training in the new technology is critical in that the sampling device must be 
rotated five times around the full circumference of the transformation zone to collect 
enough material for an adequate sample.  Care must be taken to transfer all the cellular 
material on the head of the broom or the head of the broom itself if using the AutoCyte-
Prep, into the vial immediately (Gray and McKee, 2003). 
 
Material management should also be seriously considered.  The delivery of supplies of 
preservative fluid to the health professionals and clinics and storage space within those 
clinics should be identified.  Vials of preservative fluid have a long shelf life but storage 
and stock control of collection fluid is required.  The transport of cell suspensions rather 
than dry glass slides to the laboratory may need different arrangements.  The vials are 
bulkier, and thus require greater capacity in the collection vehicles (Gray and McKee, 
2003). 
 
In the laboratory, an additional resource is required to produce the new slide preparations.  
Conventional cervical smears arrive in the laboratory already “prepared” and only require 
to be stained and coverslipped.   
 
Liquid-based cytology samples require preparation first and this has equipment, 
consumable and staffing resources attached to it.  In addition, since the microscopic 
appearance of liquid-based preparations differ from conventional smears, staff must learn 
how to interpret these new appearances as well as recognize new ‘alarms’ to replace the 
loss of the more familiar clues in conventional smears. 
 
Advantages of liquid based cytology 
• Clean background 
• Excellent fixation 
• Well defined nuclear detail 
• Instant preservation with no air drying artefact 
• Removal of blood and mucus 
• Smaller screening area 19-12mm2 containing 50,000 - 70,000 cells 
• Fewer fields to screen 
• Increased productivity 
• Standardization of collection and laboratory techniques 
• Reduction in unsatisfactory rates 
• Reduction in low-grade abnormality rate 
• Ability to use sample for other techniques such as HPV typing, 
immunocytochemistry or DNA probes. 
• Ability to triage women with high-grade abnormalities through adjunctive 
diagnostic tests 
• Reduction in costs of women unnecessarily referred for colposcopic assessment 
and treatment.  
 
 
Disadvantages of liquid based cytology 
• Training needed for smear takers 
• Lengthy laboratory preparation time 
• Training required to operate equipment 
• Training required to interpret the smears 
• Morphological appearance may be different from conventional preparations 
• Cost of reagents 
• Storage of reagents and vials 
• Loss of existing screener skills in interpreting conventional smears 
• Loss of ability for future staff to develop skills in conventional smear 
interpretation  
 
There is a steep learning curve and both cytotechnologists and cytopathologists must 
undertake significant additional training in order to achieve the same sensitivity and 
specificity on liquid-based preparations as for conventional smears.   
 
Cost is a major consideration and the additional cost for consumables for laboratories is 
perceived as the disadvantage of liquid-based cytology (Gray and McKee, 2003). 
 
2.4.10.2   Automation in cytology 
Various attempts have been made to automate the microscopic component of cervical 
screening, which constitutes the main element of data gathering. The microscopic 
analysis of smears is not the only area where automation can have an impact. Important 
advances have already been made in the fields of sample preparation, data storage and 
manipulation.  
Currently, machines are used to assist in staining and mounting slides, and computers are 
used to record details on patients with their results. The use of computerized data storage 
has assisted in the analysis of information and provided support to cervical screening 
programs in the production of printed results, letters and reminders to patients.   
 
Electronic data transmission permits the rapid availability of results to clinics, surgeries and other destinations where cervical 
screening information is required for the management of the service (http://www.babst.com). 
Over recent years automated devices to assist in the actual process of cervical screening 
have included: 
The Pathfinder system developed by the Compucyte Corporation augments the manual 
process by providing assistance and feedback to the screener to measure the accuracy of 
the physical process of screening. The effect of feedback and process standardization has 
been 
shown to decrease the number of missed minor abnormalities. Pathfinder may be a useful 
tool in the fields of both education and diagnosis by providing innovative management 
tools that ensure consistent high quality screening. 
 
AccuMed International Inc. developed the AcCell Series 2000 automated slide handling 
and data management system that supports much of the screening process including 
referral from the clinic, log in, work collection, primary screening, review and rescreen, 
quality 
control, and specimen archiving by image capture. The automated slide delivery is linked 
to an automated microscope and computer that enables human screening to take place. 
Cytosavant is a fully automated high-resolution image cytometer developed by 
Oncometrics Imaging Corporation and Xillix Technologies Corporation. The principle 
behind the system is to detect nuclear features that enable an objective diagnosis to be 
made. A camera captures an image at the highest spatial and photometric resolution that 
ensures the nucleus is in exact focus and precisely segmented. 150 nuclear features are 
calculated and a combination of decision tree processing and discriminate function 
analysis is used to classify cells and reject artefacts. The manufacturers aim to develop a 
procedure that eliminates 50% of samples with no squamous intra-epithelial lesions and 
to give positive samples a quantitative score that will triage patients for further follow up 
(http://www.aetna.com). 
 
 
The Autocyte of Roche Inc. consists of a highly automated microscope and slide handler 
coupled to a computer. Images are captured and displayed at high resolution for a 
cytologist to interpret. The manufacturers believe that the dual strategy of human expert 
opinion with consistent unbiased computer decisions should generate a finer net to catch 
otherwise unrecognised abnormalities. 
Neuropath's AutoPap 300 automates screening of conventionally prepared smears, it is a 
quality control device that reviews all smears classed as within normal limits and that are 
satisfactory, thus it helps to identify false negative smears and unsatisfactory slides. The 
machine consists of a high-speed video microscope and a field of view computer that 
interprets the image to provide a final classification based on object identification, object 
classification and slide classification. The system is designed to reduce the number of 
slides requiring human review, allow a laboratory to increase the number of slides 
processed, and decrease the costs per slide. Trials have shown that 60% of abnormal cells 
are identified. 
AutoPap assisted screening has shown superior sensitivity and specificity when compared 
to current practice but meticulous attention to the preanalytical stages of staining and 
presentation is required for enhanced performance. The clinical use of AutoPap as a 
primary screening device should improve the overall practice of cervical cytology as well 
as providing potential enhancement in laboratory productivity, however, the AutoPap is 
unable to classify atrophic changes and other benign cellular changes as normal. 
Neuromedical Systems Inc. developed PAPNET, which uses a two-stage process 
involving the scanning and review of slides.  Algorithmic processing is used to identify a 
set of 
potentially abnormal objects followed by neural network processing to identify abnormal 
cells.  The system selects 128 scenes with the highest neural network scores and 
electronically records the image for review by cytologists. Each case is triaged as either 
negative or requiring review with the latter being examined under a microscope. 
PAPNET has been shown to have a mean sensitivity of 97% for detecting significant 
abnormalities (http://www.aetna.com). 
 
When used with conventional microscopy, PAPNET may provide the means to improve 
the accuracy of cervical cytology as it has been shown to be a good tool in detecting false 
negative smears.  
 
When using PAPNET to rescreen smears, cytologists have found a significantly higher 
proportion of previously undetected cervical abnormalities as compared with 
conventional rescreening. Effectiveness estimates of interactive neural network assisted 
screening suggested that the sensitivity for detecting cervical epithelial abnormalities 
exceeded that of unassisted screening whether used as a substitute or an augmentation as 
PAPNET in tandem with rapid rescreening reduced the rate of false negatives in 
diagnostically difficult smears. 
 
In 1997 International Academy of Cytology task force group examined computerized 
screening devices and made a number of recommendations that encompassed previous 
guidelines set out in 1984 that demanded 100% specificity and sensitivity. The 
professional in charge of a clinical laboratory should continue to bear medical 
responsibility for diagnostic decisions made by machines. Automation should not lead to 
a reduction in neither standards nor expose the patient to any increased risk.  
 Supervisory personnel should continue a visual quality control on a percentage of slides 
diagnosed as normal, and recognition should be made that human expert opinion 
represents the gold standard.  
 
The setting of performance criteria should remain the responsibility of the regulatory 
authorities, and not the manufacturers, and the professional cytology community should 
participate in the development of procedures that improve decision-making 
(http://www.cytology-iac.org). 
 
Every cell is evaluated and screened very cautiously and reported on in a specific way 
acceptable and understandable by everybody concerned (SOP-WI-PCYTO-032).  At this 
stage, the Bethesda 2001 is in use.  This system has preferred nomenclature and 
recommendations (Davey, 2003).   
 
2.4.10.3   The Bethesda System: 
 
The terminology for cervical carcinoma precursor lesions has changed several times 
during the years.   
 
The traditional nomenclature, dysplasia and carcinoma-in-situ (CIS), has the advantage of 
being readily understood by many practitioners and being descriptive of the lesions (De 
May, 1999). 
 
Cervical intra-epithelial neoplasia (CIN) was introduced to emphasize the spectrum of 
abnormalities that these lesions represent and to help standardize treatment.   
 
 
The latest entry, the Bethesda System, divides precursor lesions into two groups:  LSIL 
and HSIL, respectively.  Equivalent terms are mild dysplasia, CIN I, and LSIL; and 
moderate dysplasia, CIN 2, and HSIL; severe dysplasia, CIN 3, and HSIL; and 
carcinoma-in-situ, CIN 3 and HSIL.  Human papilloma virus (HPV) changes and 
condyloma are considered LSIL (Apgar, et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: The Bethesda system   (Apgar, et al., 2003) 
BETHESDA SYSTEM 2001 
 
SPECIMEN TYPE: Indicate conventional smear (Pap smear) vs. liquid-based vs. other 
 
 
SPECIMEN ADEQUACY 
 
_ Satisfactory for evaluation (describe presence or absence of endocervical/transformation zone 
component and any other quality indicators, e.g., partially obscuring blood, inflammation, etc) 
_ Unsatisfactory for evaluation ... (specify reason) 
_ Specimen rejected/not processed (specify reason) 
_ Specimen processed and examined, but unsatisfactory for evaluation of epithelial abnormality 
because of (specify reason) 
 
 
GENERAL CATEGORIZATION (optional) 
_ Negative for Intraepithelial Lesion or Malignancy 
_ Epithelial Cell Abnormality: See Interpretation/Result (specify ‘squamous’ or ‘glandular’ as 
appropriate) 
_ Other: See Interpretation/Result (e.g. endometrial cells in a woman > 40 years of age) 
 
AUTOMATED REVIEW 
If case examined by automated device, specify device and result. 
 
ANCILLARY TESTING 
Provide a brief description of the test methods and report the result so that the clinician easily understands 
it. 
 
INTERPRETATION/RESULT 
 
NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY (when there is no cellular 
evidence of neoplasia, state this in the General Categorization above and/or in the Interpretation/Result section of the 
report, whether or not there are organisms or other non-neoplastic findings) 
 
ORGANISMS: 
-Trichomonas vaginalis 
-Fungal organisms morphologically consistent with Candida spp 
-Shift in flora suggestive of bacterial vaginosis 
-Bacteria morphologically consistent with Actinomyces spp. 
-Cellular changes consistent with Herpes simplex virus 
 
OTHER NON-NEOPLASTIC FINDINGS (Optional to report; list not inclusive): 
-Reactive cellular changes associated with 
-inflammation (includes typical repair) 
-radiation 
-intrauterine contraceptive device (IUD) 
-Glandular cells status post hysterectomy 
-Atrophy 
 
OTHER 
-Endometrial cells (in a woman > 40 years of age) 
(Specify if ‘negative for squamous intraepithelial lesion’) 
 
 
 
 
EPITHELIAL CELL ABNORMALITIES 
 
 
SQUAMOUS CELL 
 
-Atypical squamous cells 
- Of undetermined significance (ASC-US) 
- Cannot exclude HSIL (ASC-H) 
 
-Low-grade squamous intraepithelial lesion (LSIL) 
Encompassing: HPV/mild dysphasia/CIN 1 
 
-High grade squamous intraepithelial lesion (HSIL) 
encompassing: moderate and severe dysplasia, CIS/CIN 2 and CIN 3 
 
- with features suspicious for invasion (if invasion is suspected) 
 
-Squamous cell carcinoma 
 
 
 
GLANDULAR CELL 
 
-Atypical 
 - endocervical cells (NOS or specify in comments) 
- endometrial cells (NOS or specify in comments) 
- glandular cells (NOS or specify in comments) 
 
- Atypical 
- endocervical cells, favor neoplastic 
- glandular cells, favor neoplastic 
- Endocervical adenocarcinoma in situ 
 
- Adenocarcinoma 
- endocervical 
- endometrial 
- extrauterine 
- Not otherwise specified (NOS) 
 
OTHER MALIGNANT NEOPLASMS: (specify) 
 
 
EDUCATIONAL NOTES AND SUGGESTIONS (optional) 
Suggestions should be concise and consistent with clinical follow-up guidelines published by professional 
organizations (references to relevant publications may be included). 
 
 
 
 
 
 
The Bethesda System (Table 2) 
 
Type of smear: 
The conventional smear (Pap smear) is normally used in South Africa. 
 
Specimen adequacy: 
 
For “Satisfactory” specimens, information on transformation zone sampling and other 
adequacy qualifiers is also included.  Providing clinicians/specimen takers with regular 
feedback on specimen quality promotes heightened attention to specimen collection and 
consideration of improved devices and technologies.  Any specimen with abnormal cells 
is by definition satisfactory for evaluation.  If there is concern that the specimen is 
compromised, a note may be appended indicating that a more severe abnormality cannot 
be excluded.  At least 8 000 – 12 000 well preserved and well-visualized squamous 
epithelial cells should be present.  Ten well preserved endocervical cells or squamous 
metaplastic cells, singly or in clusters renders an adequate transformation zone 
component (Fig. 16). 
 
 
 
 
 
 
 
 
 
 
                                             Figure 16:  Satisfactory smear 
                                                              (Endocervical cells) 
                          (Taken from the Bethesda system for reporting cervical cytology) 
                                                                                                              
 
“Unsatisfactory” smears that are processed and evaluated require considerable time and 
effort (Fig.17).  Although such specimens cannot exclude an epithelial lesion, 
information such as the presence of organisms, or endometrial cells in women 40 years of 
age and older, etc., may help direct further patient management (Solomon and Nayar, 
2003). 
                                                             Figure 17: Unsatisfactory smear 
(Note - too few squamous cells). 
                                    (Taken from the Bethesda system for reporting cervical cytology) 
Negative for intraepithelial lesion or malignancy: 
When there is no cellular evidence of neoplasia, but various fungi or viruses can be 
present (Figs. 18, 19, 20 and 21). 
   
                                    
                                                  Figure 18:  Actinomyces   
        (Note -   filaments which can be found with women using an Intra-uterine contraceptive device)                           
                                     (Taken from the Bethesda system for reporting cervical cytology) 
 
 
 
       
                                
Figure 19:  Herpes viral infection 
(Note - intra-nuclear inclusions) 
                                       (Taken from the Bethesda system for reporting cervical cytology)       
The virus that caused genital herpes is sexually transmitted. Although the virus cannot be 
seen using the light microscope the cytopathic effects (Fig. 19) it causes can be seen. The 
virus is surrounded by an envelope and contains DNA; it is 120nm in diameter and 
replicates in the nucleus of squamous cells. The effects that the virus causes are cell 
fusion, intranuclear inclusions, nuclear moulding and a glassy appearance to the nuclei. 
 
Figure 20:  Candida species (pink filaments a fungal infection) 
(Note squamous cells are normal and some reactive) 
                              (Taken from the Bethesda system for reporting cervical cytology)       
Candida albicans, is sometimes known as monilia, it is the cause of thrush. In a cervical 
smear monilia is seen as budding branching hyphae (Fig. 20) that are often intertwined 
with epithelial cells. Candida albicans prefers an acid pH and is often associated with 
lactobacilli, which produce lactic acid from the glycogen present in intermediate 
squamous cells. An inflammatory process is often seen. 
 
 
Figure 21:  Trihomonas vaginalis 
(Note – pear shaped organisms with eccentrically located nucleus and eosinophilic cytoplasmic granules.  
Squamous cells are normal and some reactive) 
                             (Taken from the Bethesda system for reporting cervical cytology)       
This is protozoan that causes a sexually transmitted infection. In its live state 
Trichomonas have two flagella, but these are destroyed by fixation. The organism stains a 
slate blue colour, (Fig. 21), sometimes showing red cytoplasmic granules, and contains an 
ellipsoid nucleus. It is usually present in large numbers and clusters around the edge of 
superficial squamous cells. The cells show an inflammatory response to the infection 
with maturation of the squamous cells. Enlarged and irregular nuclei with perinuclear 
halos may be seen. 
 
 
  
 
Abnormal smears: 
ASC-US:  Criteria – The nuclei are approximately two and a half to three times the area 
of the nucleus of a normal intermediate squamous cell (Fig.22).  There is minimal nuclear 
hyperchromasia and irregularity in the chromatin distribution or nuclear shape (Solomon 
and Nayar, 2003). 
 
 
Figure 22:  ASC-US 
(Note - enlarged nuclei and orange cytoplasm) 
                               (Taken from the Bethesda system for reporting cervical cytology) 
       
ASC-H:  Criteria – Cells usually occur singly or in small groups.  The cells are the size 
of metaplastic cells (Fig. 23) with nuclei that are about one and a half to two and a half 
times larger than normal.  The n/c ratio may approximate that of HSIL. 
 Figure 23:  An example of ASC-H 
(Note - small cells, the size of metaplastic cells and high n/c ratio) 
                              (Taken from the Bethesda system for reporting cervical cytology) 
LSIL:  Criteria – The cells occur singly or in sheets.  Cytologic changes are usually 
confined to cells with mature or superficial-type cytoplasm.  Variable degrees of nuclear 
hyperchromasia are accompanied by variations in nuclear size, number, and shape.  
Binucleation and multinucleation are common.  The cells have distinct cellular borders.  
Perinuclear cavitation (“koilocytosis”), consisting of a sharply delineated clear 
perinuclear zone (Fig. 24) and a peripheral rim of densely stained cytoplasm, is a 
characteristic feature but not required for the interpretation of LSIL (Solomon and Nayar, 
2003). 
 
                                         Figure 24:  An example of LSIL (Note- the koilocytes) 
                             (Taken from the Bethesda system for reporting cervical cytology) 
       
Squamous Carcinoma:  Criteria – The nuclei demonstrate markedly irregular 
distribution of coarsely clumped chromatin (Fig. 25).  A tumor diathesis background 
consisting of necrotic debris and old blood is often present.  There are different variants 
of squamous carcinoma. 
 
     Figure 25:  An example of Squamous carcinoma  
(Note - the pleomorphic nuclei and prominent nucleoli) 
 (Taken from the Bethesda system for reporting cervical cytology) 
   
Adenocarcinoma:  Criteria – Adenocarcinoma is carcinoma of glandular epithelium, 
e.g., endometrium and endocervical.  Cells occur typically in small, tight clusters.  
Variation in nuclear size and loss of polarity are evident (Fig. 26).  The nuclei display 
moderate hyperchromasia, irregular chromatin distribution, and parachromatin clearing, 
particularly in high-grade tumors (Solomon and Nayar, 2003). 
 
 
                                  Figure 26:  An example of Adenocarcinoma of the endocervix 
(Note - the hyperchromasia and the nucleoli) 
                               (Taken from the Bethesda system for reporting cervical cytology)    
 
 
 
 
 
 
2.4.10.4 Consensus Guidelines for management: 
Consensus Guidelines exist which was developed by ASCCP during a consensus meeting shortly after the Bethesda meeting. 
 
 
 
 
 
               Table 3: Definitions of terms in Consensus Guidelines (Taken from Apgar, et al., 2003). 
  
Diagram 2:  Management of women with ASC-US (Taken from Apgar, et al., 2003) 
 
 Diagram 3:  Management of women with ASC-H (Taken from Apgar, et al., 2003). 
 
 
Management: 
 
The new consensus management guidelines tailored to the 2001 Bethesda System 
classification recommend different follow-up for women with ASC-US as opposed to 
those with ASC-H. 
 
Oncogenic (high-risk) HPV DNA testing is the preferred management for ASC-US when 
it can be performed concurrently with cytology; repeat cytological testing and immediate 
colposcopy also represent acceptable management. 
 
In contrast, the recommended management of ASC-H following colposcopy that does not 
result in a histological diagnosis of CIN 2 or a more severe lesion should be 
individualized based on review of all pathologic and clinical findings. 
 
Careful review is required before treating a woman with ASC-H who does not have 
histological diagnosed CIN 2 or worse (Solomon and Nayar, 2003). 
 
 
 
 Diagram 4: Management of women with LSIL (Taken from Apgar, et al., 2003). 
 
Management of LSIL: 
 
In data from the ASC-US/LSIL Triage study, high-risk HPV types were detected in 85% 
of LSIL cases, with the conclusion being that HPV testing is not a useful triage strategy. 
The ASCCP consensus guidelines recommend colposcopy for the initial management of 
LSIL. 
 
Figure 27:  Colposcopic view of cervical dysplasia (Taken from http://www.nlm.nih.gov/medline) 
 
 
  
HPV testing may have a potential role in the detection of persistent high-risk-type viral 
infection in patients with LSIL, especially because evidence has accumulated that 
persistent HPV infection is the major risk factor for “progression” (Solomon and Nayar, 
2003). 
 
 
 
 
Figure 28:  Sampling of cervix (Taken from http://www.nlm.nih.gov/medline) 
 
 Diag. 5: Management of women with LSIL in special circumstance (Taken from Apgar, et al., 2003). 
 
Diagram 6: Management of women with HSIL (Taken from Apgar, et al., 2003). 
 
 
Management of women with HSIL: 
 Most women with a cytological result of HSIL will have biopsy-confirmed CIN 2 or CIN 
3 identified at the time of colposcopy (fig. 29). 
 
Figure 29:  Cervical biopsy (Taken from http://www.nlm.nih.gov/medline) 
Therefore, the 2001 ASCCP consensus guidelines recommend that if a biopsy-confirmed 
CIN is not identified at colposcopy in a woman with a cytological interpretation of HSIL, 
all cytological and histological material should be reviewed. 
 
If the cytological interpretation of HSIL is upheld on review, a diagnostic excisional procedure should be performed (Solomon and 
Nayar, 2003) 
 
 
Diagram 7:  Management of women with AGC (Taken from Apgar, et al., 2003). 
 
 
 
Management of women with AGC: 
 
Colposcopy and endocervical and/or endometrial sampling are recommended.  If the 
histological result does not compare with the cytological findings, these slides should be 
reviewed and discussed with the clinician.  No abnormal cells on cytological findings can 
be ignored. 
All cervical smears are screened and the above nomenclature and recommendations 
followed exactly (Apgar, et al., 2003). 
 
2.4.11   Typing:  
The report is typed and handed to the pathologist.  
 
Since 2001 we have implemented the Bethesda system in our laboratory and after many 
typing errors decided to design a worksheet with canned text in order to limit the typing 
errors.  Free text can be used as and when necessary. 
 
The implementation of this worksheet (Table 4) minimized typing errors as the screener 
marks the bold printed canned text, e.g. "neg", the typists type "neg" and it expands to 
“Negative for malignant cells.”  In that way the whole report with the appropriate 
recommendations is marked or highlighted by the screener and the typists type it 
accordingly. 
 
All diagnoses with their appropriate recommendations as per Bethesda system is 
incorporated into this canned text system.  All screeners and pathologists therefore apply 
the Bethesda nomenclature and recommendations as per preset canned text.  The screener 
writes the report number and the patient’s name at the bottom of the sheet and signs her 
name to identify the screener of the slide. 
 
Staining, mounting and labeling is quality checked and marked as good or poor on the 
worksheet (Table 4).  The typist who typed the report stamps her name and the 
pathologist concerned signs if need be.  All relevant data is rechecked before the result is 
signed off and ready to be printed.  The result is now ready to be posted or e-mailed   
(SOP-WI-PHIST-500). 
 
This worksheet with the original request form is filed numerically. 
 
All abnormal slides and request forms are kept indefinitely and all normal slides with 
their request forms for a minimum of 10 years. 
 
 
Table 4:  Example of worksheet (Taken from SOP-WI-PCYTO-008) 
 
 
NATURE OF SPECIMEN 
ROUTINE PAP CX SMEAR VAULT VAGINAL ENDOPAP 
PER 
A      / B 
PEP 
A      / B 
PEC 
A      / B 
PEV 
A      / B 
PEVAG 
A      / B 
PEND 
A      / B 
ADEQUACY 
SATISFAC
TORY 
SAT 
 
ENDOCX 
 
ECC 
 
ENDOCX 
ABSENT 
ECCA 
PART OBSC 
PARTI 
 
PARTB 
POOR 
PRESERV 
CELL 
UNSAT 
REJECTED 
UNREJ 
UNSAT 
BECAUSE 
UNSAT 
……………… 
BACKGROUND 
RBCELLS 
R1     / R2     / R3 
+      /     ++     /     +++ 
NEUTS 
N1     / N2     / N3 
+      /     ++     /     +++ 
NO INFLAM 
PE43 
FLORA 
 
TRICH 
TR 
 
CANDIDA 
C 
BACTERIAL 
SHIFT 
BS 
BACT 
VAGINOSIS 
BV 
 
ACTINOMYCES 
A 
 
HERPES 
H 
 
DODER 
PEQD03 
 
CYTOLYSIS 
PEQD04 
MORPHOLOGY 
ASCUS ASCH LSIL HSIL MICRO SQ 
SQ NORMAL 
 
N 
MIXED CELL 
PATTERN 
MIXED 
SUPERF+ 
INTERM 
SI 
INTERMED 
CELLS 
I 
PARABAS 
INTERM+ 
IP 
PARAB
AS 
 
PAR 
SQ REACT 
CHANGES 
REACT 
METAPL 
 
MMETA                IMETA 
PARAKERAT 
SLIGHT/EXT 
PEQE44.1  / PEQE44.2 
HYPERKERAT 
SLIGHT/EXT 
PEQWC73.1  / PEQWC73.2 
 
GLANDULAR 
ABSENT 
ABS 
GLANDULAR 
NORMAL 
N 
GLANDULAR 
REACT 
REACT 
ENDOMETS 
PRESENT 
ENDOM 
AGC NOS 
AGC 
AGC ENDOCX 
NDOCX               NOS 
AGCX 
AGC ENDOM 
NOS 
AGCE 
AGC FAV 
NEOPL 
NAGC 
AGC ENDOCX FAV 
NEOPL 
NAGCX 
ENDOCX IN 
SITU 
AIS 
ADENOC
A 
AD 
ATYP EPITH 
CELLS 
ATYP 
DIAGNOSIS 
NEG Negative C Candida 
RASCUS ASC-US first RBV Bacterial vaginosis 
RASCP ASC-US persistent RA Actinomyces 
RASCH ASC-H RKER Para/hyperkeratosis 
RLSIL LSIL RREP Repeat 4-6 wks 
RHSIL HSIL RPE13.2 Endometrial cells  + 40years 
RAGC AGC NOS 
REA 
Endocervical cells absent 
RAGCX AGC endocervical NOS 
RCLIN 
Follow-up as clinically indicated 
RAGCE AGC endometrial NOS 
STAINING 
G    P 
TYPED BY 
  
RNAGC 
AGC favour NEOPLASIA MOUNTING G    P 
RNAGCX AGC endocervic favour 
NEOPLASIA 
LABELLING G    P 
 
 
ATRO Atrophic smear NAME 
 
 
 
  
TR Trichomonas vaginalis 
H Herpes  
04:  
 
 
 
 
2.4.12   Re-check: 
 
To reduce the possibility of incorrect assessment of smears by the laboratory, we 
introduced in 2000 a quality control procedure for all negative and inadequate smears to 
be rescreened preferably prior to sending out such reports.  These smears are currently 
subjected to shortened rescreening by a different member of staff, a method found to 
detect abnormalities missed on primary screening.  The process, referred to as “rapid 
review”, has proven to be helpful in identifying smears wrongly assessed initially as 
either adequate or inadequate, as well as for finding abnormalities  (Cross, 1997).  (Some 
laboratories also use this rapid review screening method to quickly assess a smear for on 
– site diagnoses. The slide is then later screened properly in the laboratory (Ditchmen, et 
al., 1999). 
 
Therefore, although the result is now ready and available to the doctor, (in our laboratory) 
EVERY smear is rescreened by the checker to ensure a 100% correct result.  Once again 
the patient’s history and clinical data is checked and any previous reports retrieved and 
checked according to the current slide and follow-up recommended.   
 
When a recheck shows a difference in opinion that slide and form is submitted to the 
pathologist in charge, discussed with the screener, and monitored as such on the error list.  
Amendments and recommendations may be authorized by the pathologist in charge 
(SOP-WI-PCYTO-035). 
 2.4.13   Statistics: 
 
The statistics of every screener as well as the average error rate of the laboratory is 
monitored constantly and discussed with the pathologist in charge. 
 
 
Error rate is explained by the following flow diagram: 
 
 
 
Diagr
am 8:  Flow chart of error rate 
 
 
 
2.4.13.1   Concordance rates: 
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Figure 30:  Screener concordance rates for the year 2003 
(Data taken from Ampath laboratory Port Elizabeth) 
 
 
ASC-US ratings and Error ratings are compiled and completed on a monthly basis and 
then discussed with the pathologists as well as the screeners.  
 
 
 
 
Table 5:  ERROR RATE 2002 (Data taken from Ampath laboratory Port Elizabeth)                    
 
MONTH 
 
1ST 
SCREENER 
% 
 
2ND 
SCREENER 
% 
 
3RD 
 SCREENER 
% 
 
LAB 
AVERAG
E 
NO.OF 
ABNORMAL 
SMEARS  
RECHECKED 
JANUARY 4,8 1,76 1,69 2,75 266 
FEBRUARY 2,5 1,25 0 1,85 101 
MARCH 3,8 3,4 1,11 2,7 315 
APRIL 4,4 2,6 2,5 3,25 312 
MAY 3,0 3,75 4,1 3,18 264 
JUNE 3,6 3,3 5,6 4,1 241 
JULY 3,8 3,4 2,24 4,2 335 
AUGUST 5,17 4,16 2,5 3,85 177 
SEPTEMBER 0 1,75 3,85 1,41 183 
OCTOBER 4,65 3,03 3,84 3,84 167 
NOVEMBER 2,86 4,47 3,2 3,72 160 
DECEMBER 0 3,3 3,5 2,27 63 
 3,22 3,01 2,84 3,09 2584 
 
 
Table 6:  ERROR RATE 2003      (Data taken from Ampath laboratory Port Elizabeth)                  
 
MONTH 
 
1ST 
SCREENER 
% 
 
2ND 
SCREENER 
% 
 
3RD  
SCREENER 
% 
 
LAB 
AVERAGE 
NO.OF 
ABNORMAL 
SMEARS  
RECHECKED 
JANUARY 3,1 1,59 1,64 2,11 159 
FEBRUARY 0 1,4 1,56 0,99 169 
MARCH 2,44 1,64 0 1,36 163 
APRIL 2,63 1,85 2,7 2,39 168 
MAY 2,32 1,54 1,72 1,86 169 
JUNE 5,4 3,1 2,7 3,73 180 
JULY 4,5 5,7 1,1 3,8 211 
AUGUST 2,4 2,4 1,1 1,96 218 
SEPTEMBER 1,72 0 1,37 1,03 182 
OCTOBER 1,69 2,2 0 1,3 182 
NOVEMBER 2 1,59 2,5 2,03 197 
DECEMBER 0 10 12 7,3 136 
 2,35 2,75 2,37 2,49 2134 
 
The error rates per month as per Tables 5 and 6 are calculated per screener and as per 
average for the laboratory.  This serves as a quality assurance measure and for the 
pathologist to observe when and where additional training is required (George, et al., 
2004). 
 
 
2.4.13.2   ASC-US-Rate and ASC-US-SIL Rate: 
 
ASC-US Rate:  The percentage of ASC-US results should not exceed 5% of the total 
of smears screened, when a high-risk population is screened. 
 
If the rating in the laboratory exceeds this ratio, this should be discussed immediately as 
it may be an indication of overcalling pathology (false positives and low specificity.)  
ASC-US should not be used as a collective basket for lack of making a better 
diagnosis. 
 
Table 7:  ASC-US rate (Data taken from Ampath laboratory Port Elizabeth) 
 
MONTH 
 
2001 
 
2002 
 
2003 
 
2004 
JANUARY  2,75% 2,11% 2,63% 
FEBRUARY  1,85% 0,99% 3,5% 
MARCH  2,7% 1,36% 1,7% 
APRIL  3,25% 7,18% 2,3% 
MAY  3,18% 1,86% 2,82% 
JUNE  4,2% 3,73% 3,35% 
JULY  3,85% 3,8% 4,1% 
AUGUST 5,2% 1,41% 1,96% 4,14% 
SEPTEMBER 3,9% 3,84% 1,03% 2,23% 
OCTOBER 5,16% 3,72% 1,3% 1,45% 
NOVEMBER 1,0% 2,27% 2,03% 1,89% 
DECEMBER 0,79% 3,12% 7,3% 2,42% 
Annual 
average 
 
3,21% 
 
3,0% 
 
2,89% 
 
2,71% 
 
The percentages in Table 7 show that the ASC-US rate in the laboratory is within the set limits. 
 
 
ASC-US – SIL rate:    The ratio of ASC-US to LSIL + HSIL should not be more 
than 
2-3:1 
 
 
Table 8:  ASC-US - SIL RATE 2002   RATIO SHOULD NOT BE MORE THAN 2-3:1 
(Data taken from Ampath laboratory Port Elizabeth) 
MONTH 
ASC-US L-SIL HSIL RATIO NO. OF SLIDES 
JANUARY 29 38 21 0,50:1 1594 
FEBRUARY 47 36 18 0,87:1 1737 
MARCH 112 27 11 2,90:1 1569 
APRIL 114 55 7 1,80:1 1514 
MAY 60 36 11 1,22:1 1527 
JUNE 102 30 7 2,75:1 1363 
JULY 73 29 8 2,02:1 1366 
AUGUST 51 28 11 1,30:1 1486 
SEPTEMBER 31 22 6 1,10:1 1290 
OCTOBER 34 29 5 1,00:1 1603 
NOVEMBER 21 27 8 0,60:1 1419 
DECEMBER 22 11 3 1,57:1 983 
 
 
Table 9:  ASC-US - SIL RATE 2003   RATIO SHOULD NOT BE MORE THAN 2-3:1 
(Data taken from Ampath laboratory Port Elizabeth) 
MONTH ASC-US L-SIL HSIL RATIO NO. OF SLIDES 
JANUARY 33 28 10 0,87:1 1545 
FEBRUARY 36 38 12 0,72:1 1695 
MARCH 39 42 13 0,71:1 1531 
APRIL 31 28 12 0,78:1 1344 
MAY 34 45 13 0,59:1 1732 
JUNE 32 30 7 0,86:1 1303 
JULY 39 47 5 0,75:1 1425 
AUGUST 30 29 7 0,83:1 1561 
SEPTEMBER 38 28 14 0,90:1 1350 
OCTOBER 53 37 11 1,10:1 1520 
NOVEMBER 27 29 11 0,68:1 1393 
DECEMBER 42 31 8 1,07:1 905 
 
 
 
The ratios in column 5 of both Tables 8 and 9 prove that the ASC-US-SIL rate is well 
within its normal limits at the Ampath laboratory Port Elizabeth.  
 
2.4.13.3   Follow-up letters 
 
Follow-up letters (Table 10) are also sent to submitting health professionals as a reminder to follow up patients with abnormal smears 
(Shuter, 2003). 
 
Table 10:  Example of follow-up letter (Data taken from Ampath laboratory Port Elizabeth) 
 Dr. XYZ 
October 2004 
Date Number File number Name Diagnosis Recommendation 
12/10/2004 CS1234 56 Mrs. ABC LSIL Colposcopy  
November 2004 
Date Number File number Name Diagnosis Recommendation 
2/11/2004 CS5678 78 Mrs. DEF ASC-US Colposcopy / Repeat 
smear 
December 2004 
Date Number File number Name Diagnosis Recommendation 
5/12/2004 CS9876 89 Mrs. GHI LSIL Colposcopy 
14/12/2004 CS1357 12 Mrs. JKL ASC-US Colposcopy / Repeat 
smear 
 
 
2.4.13.2   Turn around time 
 
The time from when a specimen is received in the laboratory until the result is sent out is 
logged.  Turn around time is checked twice a month.  The turn around time for the 
laboratory concerned is 6 hours.  According to SANAS regulations, all reports should be 
on the doctor’s desk within 5 days. 
 
 
 
2.4.14   Comparison with histology specimens: 
All cervical biopsies are checked for previous cervical smear results, and visa versa 
(Karateka, et al., 2004).  When the results differ, the pathologist requests the rescreening 
of the appropriate cytology slides and if he agrees with the result, he may ask for deeper 
sections of the biopsy or sometimes even requests for the biopsy to be rotated and be 
sectioned from the other side (Anderson, et al., 2004).  The pathologist will then mention 
in his report what the outcome of the comparison of cytology and histology is and make 
recommendations accordingly   (SOP-WI-PHIST-096). 
 
Cyto-histological correlation may be performed prospectively at the time of histological review.  The review may also be performed 
retrospectively.  All negative cervical cytology smears of the specific patient must be reviewed when a new HSIL or carcinoma is 
detected on smears by cytology or histology (SOP-WI-PHIST-096). 
 
 
2.5 CONCLUSION: 
Having read multiple articles, journals and books regarding the 14 points above, the 
author came to the conclusion that it will not be very cost effective to endeavour to screen 
a higher population of South African women, since there are large rural areas which do 
not have easy access to primary health care.  To get these patients to come to the urban 
areas for colposcopies, biopsies or any other recommended follow-up, seems barely 
possible and the average woman will definitely be lost for follow-up (own observation). 
 
Although screening of every female patient at least once in a lifetime is preferable in an ideal world, this is not practical due to 
financial and other constraints.  Therefore energy should be directed to at least ensuring optimal evaluation and management of the 
41% of patients who do present for cervical screening (own observation). 
 
 
 
CHAPTER 3 
 
RESEARCH DESIGN AND METHODOLOGY 
 
3.1 Study design 
 
All cervical smears received since the year 2000 to 2004 (n = +/- 61 000) will be 
retrieved from the archives of the Ampath Cytology laboratory Port Elizabeth. 
 
With the following three objectives in mind, all these smears will be evaluated and re-
evaluated accordingly: 
 
• To determine whether the presence or absence of endocervical component has an 
effect on the adequacy of cervical smears 
• To determine the impact of smaller coverslips on quality assurance in the 
cytology laboratory 
• Evaluate the effect that re-screening of smears has on quality assurance in the 
cytology laboratory. 
 
 
3.2 Data collection 
 
In this section a brief discussion will be given with regard to the data collection process, 
including techniques and procedures used. 
 
 
 
 
 
 
3.2.1 Transformation zone component: 
 
All results on all cervical smears in our laboratory since the year 2000 (n = +/- 61 000) 
were retrieved from the archives of the Cytology Ampath laboratory in Port Elizabeth 
and the presence or absence of transformation zone component calculated. 
 
3.2.2 Impact of size of coverslips on quality assurance: 
 
All abnormal cervical smears since the year 2000 (n = 5 347) were retrieved and the 
smaller coverslip measured manually on the slide.  The smaller coverslip was placed over 
the area of best concentration of cells. 
 
Therefore the smaller coverslip were sometimes placed near the frosted end of the slide 
and other times in the middle of the slide or at the end of the slide – depending on the 
way the smear was spread on the slide. 
 
 
3.2.3 Effect of 100% rescreening of slides on quality assurance: 
 
There are various methods of rescreening slides for quality assurance.  Literature shows 
that various methods have been tried and that each one has its own positive and negative 
points (Adab, et al., 2004).  Most laboratories implement the 10% quality control, which 
means that the checker chooses any one of ten smears, and rescreen this slide as quality 
control.  The author was concerned about the other 90% not being checked. 
 
Other laboratories also implemented the scan method where the slide is scanned in a step-
up and step-down manner or even scanned under a 4 X objective and only thicker areas 
on a 10 X objective or 40 X objective if need be (own observation). 
 
The use of a rapid rescreening method as part of internal quality control was implemented 
in the year 2000.  This entails the full rescreen of slide, but in a shorter time than normal.  
Literature differs, some requesting a one-minute rapid rescreen and others a 2-minute 
rapid rescreen per slide (Farrell, et al., 1997).   
 
The author takes every slide on its own merits.  If the slide is very bloody or very cellular with many inflammatory cells, more time 
will be spent on this slide opposed to a slide with less cells and with a clear background.  When the patient has had a previous 
abnormal diagnosis or abnormal clinical findings, this slide will also be rescreened more carefully (Cross, 1997). 
 
 A total of 55 583 cervical smears of 48 785 patients with a result of Negative for 
malignancy were rescreened. 
 
 
3.3 Data analysis 
 
Statistical analysis of the data was undertaken.  Some results are given in numbers and 
others as a percentage using the Microsoft Excel software package. 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
RESULTS 
 
4.1 Presence or absence of transformation zone component: 
 
The following studies were done in our own laboratory from the year 2000 to 2004. 
 Table 11:  Smears counted with present or absent transformation zone   
(Data taken from Ampath cytology laboratory Port Elizabeth) 
 No of 
smears 
Counted 
Neg. smears 
Transformation 
zone absent 
Neg. smears 
Transformation 
Zone present 
Abn. smears 
Transformation 
zone absent 
Abn. smears 
Transformation 
Zone present 
2000   3 468 1204 2141 28 95 
2001 12 657 4129 7600 204 724 
2002 15 669 4870 9412 336 1051 
2003 15 751 4847 9369 371 1164 
2004 13 387 4193 7818 296 1080 
Total 60 932 19243 36340 1235 4114 
 
 
2000: 
As per Table 11 – of the 3 468 smears counted, 1 204 (34, 72%) had negative results with 
absent transformation zone, and 2 141 (61, 74%) had negative results with present 
transformation zone. 
 
Twenty-eight (0, 8%) smears had abnormal results with absent transformation zone, and 
95 (2, 74%) smears had abnormal results with present transformation zone. 
 
 
 
 
 
2001: 
As per Table 11 – of the 12 657 smears counted, 4 129 (32, 62%) had negative results 
with absent transformation zone, and 7 600 (60, 05%) had negative results with present 
transformation zone. 
 
Two hundred and four (1, 61%) smears had abnormal results with absent transformation 
zone, and 724 (5, 72%) smears had abnormal results with present transformation zone. 
  
2002: 
As per Table 11 – of the 15 669 smears counted, 4 870 (31, 08%) had negative results 
with absent transformation zone, and 9 412 (60, 07%) had negative results with present 
transformation zone. 
 
Three hundred and thirty-six (2, 14%) smears had abnormal results with absent 
transformation zone, and 1 051 (6, 71%) smears had abnormal results with present 
transformation zone. 
 
 
2003: 
As per Table 11 – of the 15 751 smears counted, 4 847 (30, 77%) had negative results 
with absent transformation zone, and 9 369 (59, 48%) had negative results with present 
transformation zone. 
 
Three hundred and seventy-one (2, 36%) smears had abnormal results with absent 
transformation zone, and 1 164 (7, 39%) smears had abnormal results with present 
transformation zone. 
 
 
 
 
 
2004: 
As per Table 11 – of the 13 387 smears counted, 4 193 (31, 32%) had negative results 
with absent transformation zone, and 7 818 (58, 40%) had negative results with present 
transformation zone. 
 
Two hundred and ninety-six (2, 21%) smears had abnormal results with absent 
transformation zone, and 1 080 (8, 07%) smears had abnormal results with present 
transformation zone. 
 
Figure 31:  Patients counted with present or absent transformation zone 
(Data taken from cytology laboratory Ampath Port Elizabeth) 
 
 
As per Table 11 and Figure 31 a total of 60 932 smears were scanned.   
 
Of these smears, 36 340 (59, 64%) were negative for malignant cells with present 
transformation component and 4 114 (6, 75%) smears had abnormal results with present 
transformation component. 
 
Of the smears counted, 19 243 (31, 58%) smears had negative results with absent 
transformation component and 1 235 (2, 03%) smears had abnormal results with absent 
transformation component.                  
 
The total percentage of smears with absent component = 33, 61% (Table. 11). 
pts count neg. abs neg.pres abn. Abs abn. Pres
2000
2001
2002
2003
2004
  
4.2 Impact of size of coverslips on quality assurance: 
 
All abnormal cervical smears were retrieved and the smaller coverslip measured 
manually on the slide.  The smaller coverslip was placed over the area of best 
concentration of cells. 
Therefore the smaller coverslip were sometimes placed near the frosted end of the slide and other times in the middle of the slide or at 
the end of the slide – depending on the way the smear was spread on the slide. 
 
Table 12:  Abnormal smears assessed with smaller coverslips 
 
Abnormal 
Smears counted 
No of slides with 
abnormal cells 
outside small 
coverslip border 
Ratio of slides 
with cells outside 
border: total slides 
 
Percentage of abn. 
cells outside small 
coverslip border 
2000 
(1 semester) 
123 9    9:  123 7,32% 
2001 
 
928 63 63:  928 6,79% 
2002 
 
1387 52 52: 1387 3,75% 
2003 
 
1533 56 56: 1533 3,65% 
2004 
 
1376 43 43: 1376 3,13% 
Totals 5347 223     223:5347 4,17% 
 
 
 
 
2000: 
As per Table 12 - of the total number of 123 patients with abnormal results counted in the 
second semester of the year 2000, 9 smears showed abnormal cells outside the edge of 
 
 
 
 
the smaller coverslip.  This is 7, 32% of the abnormal smears screened in the second 
semester of the year 2000 that would not have been diagnosed as abnormal. 
 
2001: 
Of the total number 928 patients with abnormal results counted in the year 2001, 63 
smears showed abnormal cells outside the edge of the smaller coverslip.  This is 6, 79% 
of the abnormal smears screened in the year 2001 that would not have been diagnosed as 
abnormal. 
 
2002: 
Of the total number 1 387 patients with abnormal results counted in the year 2002, 52 
smears showed abnormal cells outside the edge of the smaller coverslip.  This is 3, 75% 
of the abnormal smears screened in the year 2002 that would not have been diagnosed as 
abnormal. 
 
2003: 
Of the total number 1 533 patients with abnormal results counted in the year 2003, 56 
smears showed abnormal cells outside the edge of the smaller coverslip.  This is 3, 65 % 
of the abnormal smears screened in the year 2003 that would not have been diagnosed as 
abnormal. 
 
2004: 
Of the total number 1 376 patients with abnormal results counted in the year 2004, 43 
smears showed abnormal cells outside the edge of the smaller coverslip.  This is 3, 13% 
of the abnormal smears screened in the year 2004 that would not have been diagnosed as 
abnormal. 
 
From the year 2000 – 2004, 4, 17% of all abnormal smears had abnormal cells only 
outside the edge of the smaller coverslip and would therefore have had false-negative 
results. 
 
This is a total of 223 smears that would have been diagnosed as false negative. 
 
 
 
 
Figure 32:  Ecto- and endocervical smear on one slide 
(Data taken from cytology laboratory Ampath Port Elizabeth) 
 
 
Taking into consideration the full size of the slide (76mm x 26mm), the frosted end 
measures 20mm x 26mm.  The rest of the slide measures 56mm x 26mm.  A large 
coverslip of 50mm x 24mm covers thus 82 % of the slide and the smaller coverslip 
measuring 40mm x 24mm covers thus 66 % of the slide.  An adequate smear consists of 
an average of at least 8000 to 12000 squamous cells (normally up to 500 000 cells). 
 
 
Due to cost saving, (Fig. 32), more and more clinicians actually place the endocervical 
smear on one half of the slide and the ectocervical smear on the other half.  In this way 
the whole slide is covered and sometimes some clinicians even put their smears over the 
frosted end of the slides.   
 
The golden rule with mounting always applies – the coverslip must be placed over the 
area with the most concentration of cells.  
 
 Figure 33:  The effect of smaller coverslips 
(Data taken from cytology laboratory Ampath Port Elizabeth) 
         
 50 x 24 mm coverslip 
  
 40 x 22 mm coverslip 
 
The black markings (high-lighted with arrows) on both slides in Figure 33, shows that 
should a smaller coverslip have been used; the abnormal cells would have been missed, 
resulting in a false negative result. 
 
In our laboratory, 223 smears would definitely been diagnosed as false negative, if the 
smaller coverslip was in use. 
 4.3 Effect of 100% rescreening of slides on quality assurance: 
 
 
The use of a rapid rescreening method (rescreening the entire smear for at least 1 – 2 
minutes) as part of internal quality control was implemented in the year 2000 (SOP-WI-
PCYTO- 035). 
 
 
A total of 48785 patients (Table 13) with 55 583 smears with negative cervical smear 
results were rescreened (some patients have more than one smear.) 
 
Table 13: Number of patients and percentages with agreements and disagreements 
 
 No of 
patients 
Minor 
disagreements 
Major 
disagreements 
Agreed upon 
 
2002 
1 semester 
18213 
 
24 (0, 
13%) 
9 (0, 05%) 18180 (99, 82%) 
2003 17304 27 
 
(0, 
16%) 
11 (0, 06%) 17266 (99, 78%) 
2004 13268 13 
 
(0, 
10%) 
7 (0, 05%) 13248 (99, 85%) 
Total 48785 64 (0, 
14%) 
27 (0, 05%) 48694 (99, 81%) 
 
 
 
Rapid rescreening was established in the Ampath laboratory Port Elizabeth in 2000 
following the publication of several studies indicating improved sensitivity for the 
detection of abnormalities in cervical smears.  During the study period, 2002 – 2004, as 
per Table 13, 48 785 patients with negative results were rapidly rescreened.  A total of 91 
patients (0, 19%) were identified with incorrect results and selected for full rescreening.   
  
Of these, 91 cases were considered inaccurate following pathologist review and resulted 
in a corrected report or an amended report.   
 
Of these, 29 cases were confirmed as ASC-US (Fig. 34).  
                    
Figure 34:  An example of ASC-US 
        (Taken from the Bethesda system for reporting cervical cytology)       
 
 
 
The nuclei of the orange streak of cells are approximately two and a half to three times the area of the nucleus of a normal 
intermediate squamous cell (Fig.34).  There is minimal nuclear hyperchromasia and irregularity in the chromatin distribution or the 
nuclear shape (Solomon and Nayar, 2003).  These cells can easily be misinterpreted if not evaluated very carefully. 
 
 
 
 
 
 
Seven cases were confirmed as ASC-H (Fig. 35). 
 
                       Figure 35:  An example of ASC-H – note two small atypical cells 
       (Taken from the Bethesda system for reporting cervical cytology)       
 
The ASC-H cells are the two small cells just off centre towards two o’clock.  
 
ASC-H cells usually occur singly or in small groups.  The cells are the size of metaplastic 
cells (Fig. 35) with nuclei that are about one and a half to two and a half times larger than 
normal.  The n/c ratio may approximate that of HSIL.  The nuclear membranes are 
irregular and sometimes indented. 
 
These cells are small and are sometimes mistaken for degenerate squamous metaplastic 
cells or atrophic parabasal-like cells. 
 
 
 
 
 
 
 Nine cases were confirmed as LSIL (Fig. 36).  
 
Figure 36:  An example of a smear with LSIL 
(Note – some smaller cells suggestive of HSIL) 
                               (Taken from the Bethesda system for reporting cervical cytology)   
      
 
The cells occur singly or in sheets.  Cytological changes are usually confined to cells with mature or superficial-type cytoplasm.  
Variable degrees of nuclear hyperchromasia are accompanied by variations in nuclear size, number, and shape.  The nuclear 
membrane is irregular and sometimes demonstrates prominent indentations or grooves.   Binucleation and multinucleation are 
common.  The cells have distinct cellular borders.  Perinuclear cavitation (“koilocytosis”), consisting of a sharply delineated clear 
perinuclear zone (Fig. 36) and a peripheral rim of densely stained cytoplasm, is a characteristic feature but not required for the 
interpretation of LSIL (Solomon and Nayar, 2003). 
 
 
 
 
 
 
 
Eleven cases were confirmed as HSIL (Fig. 37). 
                        Figure 37:  An example of a cervical smear with HSIL 
                             (Taken from the Bethesda system for reporting cervical cytology)       
 
Cytological changes affect the cells that are smaller and less “mature” than the cells in 
LSIL.  The cells occur singly, in sheets, or in syncytial-like aggregates.  Nuclear 
hyperchromasia is accompanied by variations in nuclear size and shape.  There is a 
marked increase in n/c ratio.  The chromatin may be fine or coarsely granular and evenly 
distributed.  The contour of the nuclear membrane is quite irregular and frequently 
demonstrates prominent indentations or grooves (Solomon and Nayar, 2003). 
 
A type of HSIL, where the abnormal cells are rather scattered singly than in groups or 
syncitial arrangements, can evade rapid rescreening as well as routine screening (Fig. 37).   
This suggests that even when rapid rescreening is used as a quality assurance measure, 
the “zero-error standard” is unlikely to be attained.   
 
 
 
Thirty-five results were changed in view of minor errors, i.e. wrong recommendations, 
organisms or viral infections present or lack of clinical data supplied (Fig. 38). 
  
 
 
                        Figure 38:  An example of very reactive endometrial cells due to an IUCD 
                                    (Taken from the Bethesda system for reporting cervical cytology)                      
 
 
Figure 38 demonstrates a group of vacuolated cells, some with macro-nucleoli.  In the 
absence of clinical details, these cells can be diagnosed as atypical glandular cells.  It was 
confirmed by the doctor that this patient has an IUCD, which explains these reactive and 
atypical looking endometrial cells. 
 
 
 
Rapid screening of unscreened smears could also be used as means of selecting patients 
for prompt referral when a laboratory backlog exists. This happens in a very busy 
laboratory or where the laboratory is under-staffed.   
 
The situation occurs when the screeners cannot keep up with the volume of work and a backlog of smears arises in the laboratory.  
The more urgent smears are then screened first and as the clinician phones for a result, a screener can quickly scan a smear and give 
the clinician a provisional diagnosis, then rescreen smear at own leisure.  A printed or telephonic result may then be rendered. 
 
Cytology laboratories that evaluate large numbers of slides per week may make use of 
automated screener devices as discussed in Chapter 3.  These machines are used for 
primary screening or/and as secondary screening for quality control.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
 
DISCUSSION 
 
5.1 Presence or absence of transformation zone component: 
 
The question of adequacy of cervical smears is central to the success of cervical 
screening in the prevention of cervical cancer deaths.  The problem of establishing 
exactly what constitutes an adequate sample has received increasing attention in recent 
years, culminating in various broad guidelines.   
 
The Bethesda system of terminology advocates a mandatory statement on quality of smears; grouping smears as adequate and 
inadequate.  While there is by no means unanimity over these criteria, it is important that cytologists have a degree of confidence 
about the threshold of acceptability of smear quality. 
 
The feature of paramount importance in assessing smear quality is that there should be 
adequate numbers of epithelial cells on the slide, (8000 – 12 000 well visualized 
squamous cells and 10 squamous metaplastic cells or endocervical cells) with evidence 
that they are from the appropriate area of the cervix.  In theory, the latter requirement can 
only be satisfied if squamous metaplastic cells, endocervical cells and mucus are present 
in sufficient proportions to establish that the entire circumference of the transformation 
zone has been scraped.   
 
Clearly, however, metaplastic cells will not be firmly identifiable once the transformation 
zone is fully mature, and endocervical cells will not always be sampled, especially after 
the menopause. 
 
 
   
Recognition of a representative sample therefore requires knowledge of the woman’s age 
and menstrual status and of any hormonal treatment. 
 
A smear with an abnormal result is always classified as “satisfactory” even if no transformation zone component is present. 
 
As per Table 11 (Chapter 4) a total of 60 932 smears and 59 554 patients were scanned 
(some patients have more than one smear.)  Of these smears, 36 340 (59, 64%) had 
negative for malignant cells with present transformation component results and 4 114 (6, 
75%) smears had abnormal results with present transformation component. 
 
Of the 60 932 smears counted, 19 243 (31, 58%) had negative results with absent 
transformation component results and 1 235 (2, 03%) smears had abnormal results with 
absent transformation component.                  
 
The total percentage of smears in the cytology laboratory Ampath Port Elizabeth with 
absent component results = 33, 61% (Table.11 – Chapter 4). 
 
The author is concerned about the 19 243 (31, 58%) smears with negative results and 
absent transformation component.  Our laboratory has a monthly follow-up reminder 
system in place.  This letter is delivered to every clinician concerned.  Unfortunately the 
clinicians alternate their work amongst the cytology laboratories in our area and therefore 
accurate follow-up records cannot always be maintained.  As mentioned before, HSIL 
and Adenocarcinoma (and its precursors), occur higher up in the endocervical canal.  The 
concern is thus the lesion-related errors arising from not taking smears with adequate 
endocervical or transformation zone sampling. 
 
At the laboratory concerned, all negative for malignant cells smears with absent 
endocervical or transformation zone component, except atrophic smears, vault or vaginal 
smears, has recommendations for the management of these patients.  The 
recommendation for absent component does not require a repeat smear immediately, 
unless the patient had  
high-risk HPV results within 12 months, previous squamous abnormality without 3 
subsequent negative cervical smears of which at least one contained endocervical 
component, a previous cervical smear with unexplained glandular abnormality, 
immunosuppression as well as insufficient previous screening.  A repeat smear is 
normally advised after an interval of 4 to 6 weeks to enable the epithelium some time to 
replenish.  A postpartum smear is preferred, but not mandatory for pregnant patients. 
 
A representative smear sample from the ecto- as well as the endocervix is thus required 
(own observation). 
 
Cross sectional studies have repeatedly demonstrated that smears with endocervical cells 
have a significantly higher frequency and high grade of squamous epithelial 
abnormalities detected than do smears lacking such cells (Apgar, et al., 2003).   
 
In a study of 635 patients with previous abnormal cytology referred to colposcopy, Henry 
and Solomon (1995) examined the effect of the amount of endocervical component on 
the detection of squamous lesions.  The presence of one to five endocervical cell clusters 
increased the number of HSIL cases detected from 6% to 10%.  The presence of greater 
numbers of endocervical cells had no additional effect on the detection rate of HSIL.  
Interestingly, the presence of endocervical cells did not affect the detection rate of LSIL.  
In fact, large numbers of endocervical cells actually decreased the rate of detection of 
LSIL from 21% when one to five clusters were present, to 10% when greater than 25 cell 
clusters per slide were present.  This may be a reflection of sampling too far up into the 
endocervix, thus missing lower grade lesions which are more commonly found on the 
ectocervix. 
 
Obtaining cells from the transitional zone is important, because this is where most 
cervical dysplasia is seen.  Several factors may affect the yield of endocervical cells:  
sampling technique; prior cervical procedures; surgical absence of the cervix; oral 
contraceptives; hormonal status of the patient (the transformational zone may be high 
within the endocervical canal) and pregnancy (Apgar, et al., 2003). 
 
Experts disagree on the management of the patient who lacks endocervical cells on 
cervical smear.  It is recommended that routine follow-up at prescribed intervals is 
satisfactory without an endocervical component if: there is no suspicion of a 
premalignant lesion; there is nothing of concern in the patients clinical history; there is no 
abnormality identified on physical examination; there is no history of a previous 
abnormal cervical smear and if there are no other clinical risk factors (DiSaia and 
Appleby, 2005). 
 
Although compelling, these findings are tempered by observations indicating that 
specimens without an endocervical / transformation zone component nevertheless often 
contain diagnostic cells (Apgar, et al., 2003).  These cells are thought to be probably 
originating more from the ectocervix rather than the upper endocervical canal (own 
observation).  
 
 
 
5.2 Impact of size of coverslips on quality assurance: 
Conventional cervical smears are spread onto the slide by the smear taker, and keeping in 
mind the cost of cervical smear screening as well as the number of cells on the spatula, 
the smear taker has to transfer as many cells as possible onto the slide – as evenly as 
possible. 
 
The smear taker can therefore use one half of the slide for an ectocervical smear and the 
other half of the same smear for an endocervical smear.  This is where the problem of the 
coverslip sizes arises.  As the author has proven in the findings, the larger coverslip only 
covers 82% of the slide, whereas the smaller coverslip used in this study only covers 66% 
of the slide. 
 
This is a difference of 16% of the smear surface being covered and evaluated 
cytologically. 
 
Taking into consideration that up to 300 000 cells may be on one smear, 16% of this 
smear can add up to 48 000 cells not being coverslipped and evaluated cytologically (own 
observation). 
  
Figure 32 (Chapter 4) clearly shows that the two halves of the smear differ 
macroscopically.  The doctor placed both the endocervical and ectocervical smear onto 
one slide to save costs for the patient.  It is therefore quite obvious that a 50 x 24 mm 
coverslip could not cover the whole smear (own observation).  The 40 x 24 mm smaller 
coverslip used in this study would therefore not have covered another 10mm of the 
smear, which could easily have contained the only abnormal cells on the smear. 
 
Figure 33 (Chapter 4) illustrates the 2 black markings on the top slide and the 2 black 
markings on the bottom slide.  The rule with using a smaller coverslip is to place this 
coverslip where the best concentration of cells is on the smear.  It is therefore quite 
obvious that these abnormal cells would have been missed, had a smaller coverslip been 
used (own observation). 
 
From the year 2000 – 2004, 4,17% of all abnormal smears at the Ampath laboratory in 
Port Elizabeth, had abnormal cells only outside the edge of the smaller coverslip and 
would therefore have had false-negative results. 
 
This is a total of 223 smears that would have been diagnosed as false negative. 
 
 
 
In 1998, the St Bartholomew’s Hospital in London examined 923 smears covered by 40 x 
22 mm size coverslips, inside and outside the coverslip area to determine whether this 
coverslip size could be responsible for missed abnormal cells in conventional cervical 
screening.  There was no instance when abnormal cells seen outside the coverslip were 
not also present within the coverslipped area (Oommen, et al., 1998).  Unfortunately the 
authors did not mention the size of the area of the smears on the slides examined, as 
Figure 27 (Chapter 4) illustrates endo- and ectocervical smears on one smear covering the 
greater part of the slide. 
 When the Thin-prep or AutoCyte method of preparing a smear as a liquid-based specimen is used, the size of the coverslip will not 
matter, as the cells are all spun down onto the slide into a small circle in the middle of the slide.  The smaller coverslip (some are 
round) will thus cover all the cells. 
 
The National Association of Cytologists at the Hereford laboratory in England, agrees 
that the smaller coverslip (40mm x 24mm) definitely ‘loses’ 25% of the cells on the 
smear.  David Procter (2000), points to their shortage of staff, the fact that all the cellular 
material is not transferred from the sampling device, as well as the screening errors due to 
the thousands of cells evaluated per screener per day.  The author thinks that every 
medical practitioner has to take the responsibility of his/her part of the quality assurance 
trail.  The screener can therefore not hide behind the fact that maybe some of the cells 
were not transferred to the slide, or maybe the lesion was not properly visualized 
therefore it does not matter to use smaller coverslips or make screening errors. 
 
Cytology laboratories world-wide vary with the size of coverslips they use, whether 
manual mounting or an automated mounting machine is used.  The author has proven the 
positive influence of using the larger coverslip for conventional smears, on proper quality 
assurance and correct diagnoses to which every patient is entitled.     
 
Unfortunately, the method of smear taking or preparing is not always mentioned in the 
literature when the size of coverslips are discussed.  It is therefore sometimes difficult to 
draw an accurate conclusion.   
 
At the Ampath laboratory Port Elizabeth, most smears cover the entire non-frosted area 
of the slide and therefore require the use of the larger coverslip.  The workload of the 
screener is increased by the use of the larger coverslip, but the quality assurance of each 
smear may not be compromised in any way (own observation). 
 
 
 
 
5.3 Effect of 100% rescreening of slides on quality assurance: 
 
Rescreening for quality control purposes should be conducted in a manner that 
recapitulates the laboratory’s day-to-day operations as closely as possible.  The slow, 
exaggerated rescreening that often takes place under testing or investigative 
circumstances might exaggerate the error rate, and will try to measure a type of 
performance other than that actually taking place. 
 
This reaches its peak when slides are reviewed for medico-legal purposes and one is 
monetarily compensated for lavishing enormous amounts of time on a single cervical 
smear.  One can look at the slide until cells that could never be detected by a technologist 
screening under normal laboratory circumstances are identified.  Review of slides in this 
manner bears no relationship to actual practice.  As a quality control methodology, it is 
misleading.  As an expert witness’s behaviour, it is probably unethical (Geisinger, K 
2003). 
 
This study shows that rapid rescreening definitely helps in lowering the false negative 
rate in the laboratory – with no additional effect on human resources.  The technique also 
identifies variation in the performance of screening personnel as an additional benefit, i.e. 
a screener who knows that every one of his/her slides are rescreened as a quality check, 
and the findings documented, usually screens more carefully. 
 
Rapid rescreening was established at the Ampath laboratory Port Elizabeth in 2000 
following the publication of several studies indicating improved sensitivity for the 
detection of abnormalities in cervical smears.  During the study period, 2002 – 2004, as 
per Table 11 (Chapter 4), 55 583 smears and 48 785 patients with negative results were 
rapidly rescreened.   
 
A total of 91 smears (0, 19%) were identified as incorrect and selected for full 
rescreening.  Of these, 91 cases were considered inaccurate following pathologist review 
and resulted in a corrected report or an amended report. 
 
Of these, 29 cases were confirmed as ASC-US; 7 cases were confirmed as ASC-H, 9 
cases were confirmed as LSIL and 11 cases as HSIL.  Thirty-five results were changed in 
view of minor errors, i.e. wrong recommendations, organisms or viral infections present. 
 
The laboratories that participates in the manual rescreening quality assurance program, normally only screens one of every ten slides – 
selected at random.  This is a very big concern to the author, as selecting a different random collection of slides could lead to a totally 
opposite result which negates the usefulness of 10% rescreening.  With 100% rescreening, personal random choice of slides for 
rescreening has no influencing on the error rate of the laboratory. 
 
5.3.1   Manual rescreening: 
Manual microscopic screening of cervical smears by cytotechnologists continues to be 
the most widely used and accepted method of identifying irregular cells on cellular 
abnormalities of the cervix (Cronje, 2004).   
 
At the Ampath laboratory in Port Elizabeth, rapid rescreening of all negative, inadequate 
as well as abnormal smears is the quality control method of choice.  Rapid rescreening 
was easily incorporated into the workflow and it is an effective quality assurance 
technique resulting in the detection of increased numbers of abnormal smears The 
calculated concordance rate of the screeners in this laboratory is averaging 99, 81%.  This 
laboratory has an interlaboratory quality assurance program, by comparing the cytology 
results with that of the histology results.  The external quality assurance program of the 
laboratory has been implemented since 2002.  The various cytology laboratories in Port 
Elizabeth rotate and discuss interesting cases every second Wednesday morning. 
 
At the United Leeds Teaching Hospital in Leeds, rapid rescreening of all negative and 
inadequate smears is the quality control method of choice.  The sensitivity of primary 
screening of laboratories and individual screeners are major indicators of screening 
quality and are dependent on the number of false negative smears found by rapid 
screening their calculation.  High sensitivity may indicate good quality primary screening 
or poor quality rapid review.  The calculated sensitivity in this laboratory ranged from 
92-54% for high-grade abnormalities and 75-33% of all grades, revealing a wide range of 
performance between individual prescreeners.  The authorities of this laboratory advise 
that partial rapid rescreening be considered as the quality control method of choice 
(Brooke, et al., 2002).  The author notes that certain laboratories use prescreeners to 
divide the smears into two groups – normal and abnormal, before the work is given to the 
screeners to evaluate.  This method is not cost effective in the Ampath laboratory Port 
Elizabeth (own observation). 
 
At the Laboratory at the Hospital Jeanne de Flandre in France, the author confirms that 
cytology manual screening is the most appropriate means of screening for cervical 
cancers and pre-malignant lesions.  This laboratory has an interlaboratory quality 
assurance program, by comparing the cytology results with that of the histology results.  
They came to the conclusion that the invasive cervical cancers still observed in France 
can be attributed to the lack of screening experience, lack of management and cytological 
false negative results.  They found that the conditions for optimizing screening are wide 
coverage of good quality smears, competent cytologists and the appropriate follow-up 
system of abnormal smears (Leroy & Boman, 2003).  The findings of the authors of this 
laboratory, underlines the 14 contributing factors for absolute quality assurance as 
discussed in Chapters 1, 2, and 3  (own observation). 
 
The division of Cytology, Boston, Massachusetts, United States of America, wanted to 
determine the reliability of the false negative rate of cervical cytological screening by 
rapid rescreening.  The test set consisted of 401 cases (311 originally diagnosed as 
negative, 74 as ASCUS, 14 as LSIL and two as HSIL) and were rapidly (30 seconds) 
rescreened.  Five cytotechnologists with no prior experience in rapid rescreening were 
tested to evaluate the cases for false negative rating of rapid rescreening and primary 
screening.  Their conclusion was that the false negative rate of rapid rescreening was 
relatively reproducible though the individual cases identified varied between reviewers.  
They found that rapid prescreening is the most logistically simple method to determine 
the true false negative rate of the laboratory (Renshaw, et al., 1999). 
  
 
The Department of Anatomical Pathology, Queensland Medical laboratory, Brisbane, 
Australia, had rapid rescreening established in their laboratory in 1995.  During this 
period, 285 841 negative smears (representing 89, 09% of the total workload) were 
rapidly rescreened and a total of 7 650 (2, 68%) were identified as abnormal or suspicious 
and selected for full rescreening.  They found that rapid rescreening was easily 
incorporated into their workflow and that rapid rescreening was an effective quality 
assurance technique resulting in the detection of increased numbers of abnormal smears 
(Wright, et al., 1999). 
 
A Danish laboratory has found that partial manual rescreening of all negative smears is 
recommended as the most cost-effective method of internal quality control.  The method 
was tested by 8 cytotechnologists and the average diagnostic sensitivity, assessed upon 
their answering of 200 test smears (150 negative and 50 positive) was 80%, while 
specificity was calculated as 95%.  Partial rescreening was here-upon used in daily 
routine.  After one year 21 000 smears have been rescreened.  Twenty-nine cases of false 
negatives, 16 with atypia, 8 with koilocytosis, and 5 cases with dysplasia have been 
detected, which corresponds to an overall false negative rate of 3%.  In 5 of the 29 false 
negative cases with dysplasia, histological follow-up has shown 4 cases of HSIL, and one 
case of LSIL.  Conclusively, partial rescreening of all negative smears implies an 
improved quality with reduction of the number of false negative specimens (Jensen, et 
al., 2000).  
 
 
5.3.2   Automated rescreening: 
In the United Kingdom, areas of Europe and United States of America, there is a shortage of qualified cytotechnologists as well as 
pathologists.  These laboratories do not have the staff complement for 100% rescreen and most of them have tried and/or implemented 
the Automated Papanicolaou smear analysis as a screening tool.   
 
The various laboratories had different findings:  
  
 
Reviews conducted for the United States Preventive Services Task Force and the Agency 
for Healthcare Research and quality showed the following:  New technologies intended to 
improve detection of cytological abnormalities included liquid-based, thin-layer cytology 
(ThinPrep, AutoCyte), computerized rescreening (PAPNET), and algorithm-based 
computer rescreening (AutoPap).  Fourteen % to 33% of the cases failed to detect 
abnormalities that existed at the time of screening.   
 
Using standard criteria for evaluation of the diagnostic tests, the authors determined that 
knowledge about the sensitivity, specificity, and predictive values of new technologies, 
was meagre.  Lack of an adequate reference standard was the overwhelming reason that 
test characteristics could not be properly assessed or compared.   
 
Most publications compared results of screening using the new technology with expert 
panel review of the cytological specimen.  In that case, the test was found not to have 
independent measures and does nothing to relate the screening test findings to the true 
status of the cervix, making determination of false-negatives, and thus sensitivity, 
specificity, and negative predictive value, impossible.   
 
The current evidence for the purposes of guiding decision making about choice of 
screening tools, proved inadequate to gauge whether new technologies are “better” than 
conventional cytology (Hartmann, et al., 2001).  The fact that these computerized 
rescreening technologies failed to diagnose 14% to 33% of abnormalities already 
diagnosed at the time of manual screening, is very alarming and proves to the author that 
the 100% manual rescreen is much better and much more cost-effective (own 
observation). 
   
The department of Cellular Pathology, Washington, DC 20306-6000, USA approved 
several devices that use computerized image analysis to rescreen cervical smears that 
have already been examined by cytotechnologists.  The objective was to determine the 
effectiveness and cost of PAPNET-assisted rescreening in identifying cervical 
abnormalities not identified by manual rescreening.   
 
PAPNET-assisted rescreening of 5478 cervical smears previously identified as “within 
normal limits” or “benign changes” on both initial and random screening was 
implemented.    The smears were rescreened by PAPNET, followed by re-evaluation of 
abnormal smears by the consensus panel; consisting of 3 cytotechnologists and 3 
pathologists PAPNET screening identified 1614 (29%) slides requiring additional 
microscopic review.  On further review, 448 (8% of total) had possibly abnormal cells.   
 
Ultimately, 11 of these cases were reviewed by the consensus panel for potentially 
atypical cells.  Of these 11 cases, 5 were reclassified as ASC-US and one as AGUS; the 
patient with the diagnosis of AGUS on rescreening was diagnosed as having LSIL on 
follow-up (O’Leary, et al., 1998).   
 
Five cases of ASC-US was therefore found from 5 478 smears of which the PAPNET 
originally identified 1 614 slides as requiring additional microscopic review – a pick-up 
rate of 0,09% compared to the 0,19% pick-up rate of the Ampath laboratory in Port 
Elizabeth with 100% rescreen (a two-fold increase in pick-up rate).    
 
The author is concerned that only 5 ASC-US cases were identified and no ASC-H, LSIL, 
HSIL or higher-grade lesions were found.  With the 100% manual rescreen in the 
Ampath laboratory, all grades of intra-epithelial lesions were found and as discussed 
before, the ASC-H cells can be very few and single-lying and easily interpreted 
incorrectly (own observation).  Does the automated rescreening technology have a 
problem interpreting the smaller, single-lying abnormal cells? 
 
The Department of Obstetrics and Gynaecology in Los Angeles, California, screened 3 
271 patients by simultaneous cervical smears and cervigram, a non-invasive photographic 
method introduced for screening.  The accuracy of each screening test, when positive or 
suspicious, was evaluated independently and the results compared with colposcopically 
directed biopsy results.  The cervigram was significantly more sensitive than the cervical 
smear, whereas the cervical smear was significantly more specific than the cervigram in 
detecting cervical intra-epithelial neoplasia (Tawa, et al., 1998). 
 
The Medical College of Wisconsin screened 1200 cervical smear slides with negative 
findings using the PAPNET screening system.  Screening with PAPNET identified 8 
patients with ASC-US that were not diagnosed on initial screening, yielding a false-
negative rate of 0, 7% for ASC-US.  No LSIL’s or HSIL’s were identified.  The rate of 
changed diagnoses in the PAPNET group was similar to the rate in the laboratories 
standard rescreening of 10% of all smears with negative findings.   
 
The mean turnaround time for a PAPNET screen was 13, 9 days, compared with 3, 9 
days for manual review.  The conclusion that this laboratory came to, was that for a 
laboratory with a low percentage of smears with abnormal findings, a quality 
cytotechnologist and pathologist, and required quality assurance standards in place, 
PAPNET may not improve the pick-up rate for missed cervical lesions, and may add 
significantly to the cost and turnaround time of cytological evaluation of smears 
(Brotzman, et al., 1999). 
 
At The Erasmus University in Rotterdam, The Netherlands, the outcome of having a 10% 
manual recheck as apposed to PAPNET recheck, was that although PAPNET was found 
to be time saving as compared to conventional microscopy, the associated reduction in 
personnel costs is outweighed by the costs of scanning the slides and additional 
equipment.  Using PAPNET instead of conventional microscopy as a primary screening 
tool will make cervical cancer screening less cost-effective unless the costs of PAPNET 
are considerably reduced and its sensitivity and/or specificity are considerably improved 
(Meerding, et al., 2001). 
 
At a laboratory in France, the effectiveness of the PAPNET System was compared with 
conventional screening.  Three thousand ninety-seven negative cervical smears were 
rescreened manually and with the PAPNET system.  There were two reviews of the 
PAPNET images.  The first by two cytotechnologists with limited exposure to the 
instrument, and the second, limited to smears with discrepant diagnoses, by an expert in 
using the system.  The results of the smears resreened were compared with available 
biopsies. On manual resreening of the 3 097 smears, 2 901 (93, 66%) were reported as 
negative and 170 (5, 49%) as abnormal.  On the PAPNET review, 2 938(94, 87%) of the 
smears were reported as negative and 150 (4, 84%) as abnormal.  There were 144 smears 
with discrepant diagnoses.  When compared to the results of the biopsies, PAPNET-
assisted rescreening agreed much better with the consensus diagnosis than did manual 
rescreening.  The laboratory has implemented a system where the highest rate of 
specificity as well as sensitivity is obtained (Bergeron, et al., 2000).  
 
 
5.4 Conclusion: 
 
5.4.1   Presence or absence of transformation zone component: 
The feature of paramount importance in assessing smear quality is that there should be adequate numbers of epithelial cells on the 
slide, (8000 – 12 000 well visualized squamous cells and 10 squamous metaplastic cells or endocervical cells) with evidence that they 
are from the appropriate area of the cervix.  A smear with an abnormal result is always classified as “satisfactory” even if no 
transformation zone component is present. 
 
As per Table 11 (Chapter 4) a total of 60 932 smears were scanned 
 
The author is concerned about the 19 243 (31, 58%) patients with negative results and 
absent transformation component.  The concern is thus the lesion-related errors arising 
from not taking smears with adequate endocervical or transformation zone sampling.  At 
the laboratory concerned, all negative for malignant cells smears with absent 
endocervical or transformation zone component, except atrophic smears, vault or vaginal 
smears, has recommendations for the management of these patients.  The 
recommendation for absent component does not require a repeat smear immediately, 
unless the patient has had high-risk HPV results within 12 months, previous squamous 
abnormality without 3 subsequent negative cervical smears of which at least one 
contained endocervical component, a previous cervical smear with unexplained glandular 
abnormality, immunosuppression as well as insufficient previous screening.  A repeat 
smear is normally advised after an interval of 4 to 6 weeks to enable the epithelium some 
time to replenish.  A postpartum smear is preferred, but not mandatory for pregnant 
patients. 
 
5.4.2   Impact of size of coverslips on quality assurance: 
Cytology laboratories world-wide vary with the size of coverslips they use, whether they 
use manual mounting or an automated mounting machine.   
 
At the Ampath laboratory Port Elizabeth, most smears cover the entire non-frosted area 
of the slide and therefore require the use of the larger coverslip.  The workload of the 
screener is increased by the use of the larger coverslip, but the quality assurance of each 
smear may not be compromised in any way (own observation). 
 
The author has proven the positive influence of using the larger coverslip for 
conventional smears, on proper quality assurance and correct diagnoses to which every 
patient is entitled.     
 
Figure 33 (Chapter 4) illustrates the 2 black markings on the top slide and the 2 black 
markings on the bottom slide.  The rule with using a smaller coverslip is to place this 
coverslip where the best concentration of cells is on the smear.  It is therefore quite 
obvious that these abnormal cells would have been missed, had a smaller coverslip been 
used (own observation). 
 
From the year 2000 – 2004, 4, 17% of all abnormal smears had abnormal cells only 
outside the edge of the smaller coverslip and would therefore have had false-negative 
results. 
 
 
This is a total of 223 smears that would have been diagnosed as false negative. 
  
 
 
 
 
 
 
 
5.4.3   Effect of 100% rescreening of slides on quality assurance: 
The author comes to the conclusion that the automated screening technologies have been 
tested globally, but seems too expensive and its sensitivity and specificity not completely 
up to standard.   
As discussed above, every laboratory has its own perception and findings on the quality 
control of screening.   
 
In South Africa the cost of automated rescreening is far too high and manual rescreening 
is depended on.  All abnormal smears are rescreened by a ‘checker’ and then taken to the 
pathologist (if necessary).  It is also the screener’s prerogative to hand any smear that 
they are unsure of, to the checker.  The checker also rescreens the smears of all high-risk 
patients.  At the Ampath laboratory in Port Elizabeth, all negative smears are rapid 
rescreened.  Rapid rescreening was established in the laboratory in 2000 following the 
publication of several studies indicating improved sensitivity for the detection of 
abnormalities in cervical smears. 
 
A total of 48 785 patients with Negative for malignant cells results were rescreened. 
 
A total of 91 cases (0, 19%) were identified as incorrect and selected for full rescreening.   
 Manual rescreening has a higher sensitivity and specificity and is much more cost 
effective. 
 
 
 
 
CHAPTER 6 
 
SUMMARY AND RECOMMENDATIONS 
 
Since cervical cancer is the most common malignancy amongst women in developing 
countries, the medical profession will have to endeavour to screen a higher rate of women 
and ensure a 100% quality assurance with every patient treated in order to reduce the 
unacceptable high incidence rate of cervical carcinoma.  The question arises why patients 
present with advanced cervical disease ab initio in countries where cervical screening 
programs are available.  This is regarded as a failure of cervical smear screening. 
 
Therefore we have to concentrate on QA to ensure the quality of cervical pathology in the 
41% of patients who present for cervical screening. 
 
As discussed, factors contributing to QA entail a variety of actions which to a lesser or 
greater extent influences the final diagnosis and follow-up of patients with cervical 
pathology. 
 
6.1. Taking of smear: 
Taking of cervical smears forms the most integral part of quality assurance.  With the 
patient in the lithotomy position, the clinician should visually inspect the cervix and 
identify the transformation zone.  Both a representative endo- and ectocervical sample 
should be taken.  The percentage of absent transformation zone for normal and abnormal 
smears are 33, 61% in our laboratory.   
 
6.2. Fixation of smear: 
Rapid fixation is essential to ensure the cells are well preserved.   
 
 
 
 
6.3. Marking of slide 
The slide should immediately be marked on the frosted end of the slide with a pencil or 
diamond pen thus preventing slides being mixed up with other patient’s forms, resulting 
in the incorrect slide being screened with the incorrect form.   
 
 
6.4. Submission of clinical data 
Laboratory test results are of limited use in the absence of corresponding clinical 
information. Clinical information is critical for the technologists, pathologists and 
clinicians alike with the ultimate goal of optimal patient care. 
 
6.5. Transportation of cervical smears 
Timeous fixation is the perfect “transport medium” for a cervical smear and this fixation 
will keep the cells in perfect condition for a couple of days.  No ice packs or additional 
transport medium is needed. 
 
6.6. Receiving smears in laboratory 
Training on the receipt of specimens in the laboratory is regarded as of utmost 
importance as NO mistakes may be allowed here.  The information on the slide is 
compared with those on the form, and if correct, the slide is assumed to belong to that 
form and both the slide and the form are allocated a unique laboratory number.   
 
6.7. Staining of slides 
Before any diagnosis can be made on any slide, the slide needs to be stained by various 
stains to enable the screener to interpret the cells with the aid of a microscope.  The 
normal Haematoxylin – Eosin Pap stain is usually used. 
 
6.8 Mounting 
Since xylene is a known carcinogen, all mounting of slides should be done under an 
extractor fan.  Entellan of DePex can be used as a mounting medium.  The size of the 
coverslips used is a very important component of quality assurance.  By using the 50 x 24 
mm size coverslip in our laboratory, 4, 17% (223) of our smears were correctly diagnosed 
as positive.    
 
6.9   Labeling 
Before a slide is labelled, the name and number on the slide as well as the form is 
compared and the appropriate label is attached to the frosted end of the slide.   
 
6.10 Screening and reporting 
Manual microscopic screening of cervical smears by cytotechnologists continues to be 
the most widely used and accepted method of identifying irregular cells on cellular 
abnormalities of the cervix.   
 
6.10.1   Liquid-based preparations 
Liquid based cytology, or thin layer cytology, is a technique of preparing a monolayer of 
cells on a glass slide.  The technique involves suspending the sample in a solution that is 
both mucolytic and haemolytic. The sample is concentrated either by centrifugation or by 
filtration.  In the former method a monolayer of cells sediments onto the slide, in the 
filtration method a monolayer of cells is pressed onto the slide from the filter. 
6.10.2   Automation in cytology 
Various attempts have been made to automate the microscopic component of cervical 
screening, which constitutes the main element of data gathering. The microscopic 
analysis of smears is not the only area where automation can have an impact. Important 
advances have already been made in the fields of sample preparation, data storage and 
manipulation.  
Currently, machines are used to assist in staining and mounting slides, and computers are 
used to record details on patients with their results.  The use of computerized data storage 
has assisted in the analysis of information and provided support to cervical screening 
programs in the production of printed results, letters and reminders to patients.  
Automation of cytology screening was tried in South Africa, but found to be too 
expensive and the specificity and sensitivity not up to standard. 
 
 
6.11   Typing 
Since 2001 The Bethesda system has been implemented in the Ampath laboratory Port 
Elizabeth and after many typing errors, it was decided to design a worksheet with canned 
text in order to limit the typing errors.  Free text can be used as and when necessary.  All 
diagnoses with their appropriate recommendations as per Bethesda system is incorporated 
into this canned text system.  All screeners and pathologists therefore apply the Bethesda 
nomenclature and recommendations as per preset canned text.   
 
6.12   Re-check 
To reduce the possibility of incorrect assessment of smears by the laboratory, a quality 
control procedure was introduced in 2000 for all negative and inadequate smears to be 
rescreened preferably prior to sending out such reports.  The process, referred to as “rapid 
review”, has proven to be helpful in identifying smears wrongly assessed initially as 
either adequate or inadequate, as well as for finding abnormalities.  The 100% recheck 
definitely aids in the diminishing of the ‘false negative rate.’  Ninety-one (0, 19%) false-
negative cases were found with the rapid rescreen.   
 
6.13   Statistics 
The statistics of every screener as well as the average error rate of the laboratory is 
monitored constantly and discussed with the pathologist in charge. 
 
Error rate is: 
1.   Concordance rates:  Agreement rate of all screeners and the average of laboratory.  
This is monitored monthly (99, 81% in Ampath laboratory Port Elizabeth). 
2.  ASC-US Rate:  The percentage of ASC-US results should not exceed 5% of the total 
of smears screened, when a high-risk population is screened.  ASC-US should not be 
used as a collective basket for lack of making a better diagnosis.  (Within normal limits in 
Ampath laboratory Port Elizabeth.) 
3.  ASCUS – SIL rate:  The ratio of ASCUS to LSIL + HSIL should not be more than 
2-3:1 (Within normal limits in Ampath laboratory Port Elizabeth.) 
 
 
6.14. Comparison to histology specimens 
Correspondence with biopsies, etc. received in histology laboratory with a result of 
previous cervical smear or previous histology report.  The cytology and histology result 
should be compared and even reviewed in certain cases.  Should the two results differ 
considerably, this should be discussed with the submitting health practitioner and 
recommendations decided upon. 
 
 
6.15 Recommendation: 
 
Quality assurance is a full-time never-ending task that each medical professional should 
be completely committed to at all times.  Any ‘problem’ in the laboratory, that can affect 
the quality of the results of the smears, should be rectified as a matter of urgency.  The 
quality of the cytology results at any laboratory may not be compromised.  We should 
endeavour to implement the QA procedures at all hospitals, clinics and laboratories, to 
ensure the highest possible degree of quality assurance at all times. 
 
Every person involved with any facet of the medical profession should endeavour to 
comply to the quality assurance rules completely.  In this way, the 41% of women that do 
go for cervical smears can be assured of the correct diagnosis, the correct follow-up 
system and the correct treatment.  With the follow-up letters in place, the ‘lost to follow-
up’ risk is diminished and the use of the bigger coverslip ensures that as many cells as 
possible on every smear, is screened and evaluated.   
 
 
 
Quality assurance is therefore the key word in every laboratory! 
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